

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 June 2011 (03.06.2011)

PCT

(10) International Publication Number
WO 2011/063531 A1

(51) International Patent Classification:

A61K 47/14 (2006.01) A61P 29/00 (2006.01)
A61K 31/192 (2006.01)

(21) International Application Number:

PCT/CA2010/001899

(22) International Filing Date:

26 November 2010 (26.11.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/264,724 27 November 2009 (27.11.2009) US

(71) Applicant (for all designated States except US): **NUVO RESEARCH INC.** [CA/CA]; 7560 Airport Road, Unit 10, Mississauga, Ontario L4T 4H4 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KING-SMITH, Dominic** [GB/US]; 5814 Lord Cecil St., San Diego, California 92122 (US). **GALER, Bradley** [US/US]; 1740 Lenape Road, Bldg. 2, West Chester, Pennsylvania 19382 (US). **NEWSAM, John, M.** [US/US]; 525 Westbourne St., La Jolla, California 92037-5449 (US). **BUYUK-TIMKIN, Nadir** [US/US]; 11772 Carmel Creek Road,

#105, San Diego, California 92130 (US). **BUYUK-TIMKIN, Servet** [US/US]; 11772 Carmel Creek Road, #105, San Diego, California 92130 (US). **KISAK, Edward, T.** [US/US]; 3525 Bayside Lane, Apt. B, San Diego, California 92109 (US). **SINGH, Jagat** [CA/CA]; 64 Grover Drive, Toronto, Ontario M1C 4V7 (CA).

(74) Agent: **BERESKIN & PARR LLP/S.E.N.C.R.L., S.R.L.**; 40 King Street West, Suite 4000, Toronto, Ontario M5H 3Y2 (CA).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,

[Continued on next page]

(54) Title: TOPICAL IBUPROFEN FORMULATIONS

Figure 1



(57) Abstract: The present application relates to a topical formulation comprising ibuprofen, a hydroalcoholic based solvent system, a C₁₋₄ alcohol ester of citric acid, and a surfactant. The formulation shows physical stability over more than one month at ambient temperature and is colourless, essentially odourless, and has a pH value of about 6.5. The formulation of the application shows two to four times improved ibuprofen flux compared to a standard composition.

WO 2011/063531 A1

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). — *of inventorship (Rule 4.17(iv))*
Published: — *with international search report (Art. 21(3))*

Declarations under Rule 4.17:

Title: Topical Ibuprofen Formulations

[0001] The present application claims the benefit of priority from co-
5 pending U.S. provisional patent application number 61/264,724, filed on
November 27, 2009, the contents of which are incorporated herein by
reference in their entirety for all purposes.

Field of the Application

[0002] The present application relates to topical ibuprofen formulations,
10 methods for their preparation and their use for the topical treatment of pain.

Background of the Application

[0003] Ibuprofen, or 2-(4-isobutylphenyl)propanoic acid, is a member of
the propionic acid group of non-steroidal anti-inflammatory drugs ("NSAIDs").
Ibuprofen was originally marketed in oral form as Brufen™, and since then
15 under various other trademarks, including Nurofen™, Advil™ and Motrin™.
Ibuprofen is used for relief of symptoms of arthritis, primary dysmenorrhea,
fever and as an analgesic, especially where there is an inflammatory
component.

[0004] Ibuprofen occurs as *[+]*S- and *[-]*R-enantiomers and as a
20 racemic mixture of the two. It is a white to off-white crystalline powder,
practically insoluble in water (<0.1 mg/mL), but readily soluble in polar organic
solvents such as ethanol and acetone.

[0005] Current topical formulations of ibuprofen that are available
include, for example, Ibugel™, Ibuleve™ (5% ibuprofen gel), Deep Relief™
25 Dual Action Gel (5% ibuprofen, 3% levomenthol gel), Nurofen™ (10%
ibuprofen gel), Booths Ibuprofen Gel (5% ibuprofen gel) and Sainsbury's
Ibuprofen Pain Relief Gel (10% ibuprofen gel).

[0006] Various factors can affect the absorption rates and penetration
depth of topical pharmaceutical preparations, including the nature of the
30 active ingredient, the nature of the vehicle, the pH, and the relative solubility
of the active in the vehicle versus the skin [Ostrenga J. *et al.*, Significance of

vehicle composition I: relationship between topical vehicle composition, skin penetrability, and clinical efficacy, *Journal of Pharmaceutical Sciences*, 60: 1175-1179 (1971)]. More specifically, drug attributes such as solubility, particle size and charge, as well as vehicle attributes such as the drug
5 dissolution rate, spreadability, adhesion, and ability to alter membrane permeability can each have significant effects on penetration.

[0007] Seemingly minor variations in formulations can produce significant changes in their performance. For instance, Naito *et al.* demonstrates significant variability in penetration among topical NSAID
10 formulations simply by changing the gelling agent used in the compositions [Naito *et al.*, Percutaneous absorption of diclofenac sodium ointment, *Int. Jour. of Pharmaceutics*, 24: 115-124 (1985)]. Similarly, Ho noted significant variability in penetration by changing the proportions of alcohol, propylene glycol, and water [Ho *et al.*, The influence of cosolvents on the in-vitro
15 percutaneous penetration of diclofenac sodium from a gel system, [*J. Pharm. Pharmacol.*, 46:636-642 (1994)]. It was noted that the changes affected three distinct variables: (i) the solubility of the drug in the vehicle, (ii) the partition coefficient of the drug between the vehicle and the skin, and (iii) the alteration of skin structure [*Id.*].

[0008] Ho *et al.* also noted that (i) the pH of the vehicle, (ii) the drug
20 solubility, and (iii) the viscosity of a gel matrix can influence penetration from a gel dosage form [*Id.*]. The pH value affects the balance between the ionized and non-ionized forms of the drug, which typically have different permeation properties [Obata, *International Journal of Pharmaceutics*, 89: 191-198
25 (1993)]. The viscosity can affect diffusion of the drug through the gel matrix and release of the drug from the vehicle into the skin. The solubility of the drug in the vehicle will affect the partition coefficient of the drug between the composition and the recipient membrane or tissue [Ho, *Id.*].

[0009] The skin barrier can be compromised by several physical
30 methods, such as iontophoresis, ultrasound, electroporation, heat, and microneedles. Molecular penetration enhancers (MPE™s) are a preferred

means for reversibly reducing the skin barrier. At least 400 chemicals have been identified as skin permeability enhancers. General categories of MPE™s include pyrrolidones, fatty acids, fatty acid esters, fatty acid alcohols, sulfoxides, essential oils, terpenes, oxazolidines, surfactants, polyols, azone
5 and derivatives, and epidermal enzymes.

[0010] The mechanisms by which MPE™s reduce the skin barrier function are not well understood [see Williams and Barry "Penetration Enhancers" *Advanced Drug Delivery Reviews* 56: 603-618 (2004)], although it has been proposed that the mechanisms can be grouped into three broad
10 categories: lipid disruption, increasing corneocyte permeability, and promoting partitioning of the drug into the tissue.

[0011] The challenge with use of MPE™s is that few seem to induce a significant or therapeutic enhancement of drug transport at tolerable levels. This is because an MPE™s disruption of the skin barrier can potentially
15 cause skin irritation, damage or both. With increased disruption, skin irritation is expected to become a greater issue. This is particularly problematic with topical pain treatments where the goal is to have the active penetrate deeply into the underlying tissue or where the drug must be used on a long-term basis due to the nature of the pain.

[0012] In light of the foregoing, there is a considerable need for the development of topical ibuprofen formulations suitable for use in the treatment of pain. The challenge has been to develop an optimal composition which will deliver the active agent to the underlying tissue in sufficient concentration to treat pain, while reducing or minimizing the incidence of skin irritation caused
20 by disrupting the skin barrier and while providing a composition and dosage
25 that leads to and encourages patient compliance.

Summary of the Application

[0013] A series of hydroalcoholic-based compositions that comprise, in addition to water and alcohol(s), ibuprofen, triethyl citrate and a surfactant,
30 have been prepared and shown to possess 2 to 4 times greater flux than a currently available standard ibuprofen topical formulations. These

compositions have shown physical stability over more than one month at ambient temperature and are colourless, essentially odorless and have pH values in the range of about 3 to 7, or about 6.5.

[0014] Accordingly, the present application includes a composition comprising ibuprofen, a hydroalcoholic-based solvent, a C₁₋₄alcohol ester of citric acid and a surfactant, wherein the composition is formulated for topical administration.

[0015] The presence of a C₁₋₄alcohol ester of citric acid (for e.g. triethyl citrate) and a surfactant together in the composition is beneficial for ibuprofen delivery. Compositions without surfactant precipitate after about 24 hours at room temperature (RT). In the absence of triethyl citrate the compositions are not homogeneous and some reduction in permeation through the skin is observed. In the absence of both triethyl citrate and surfactant, precipitation is observed.

[0016] The present application also includes a method for treating pain comprising applying an effective amount of a topical ibuprofen composition of the application to a subject in need thereof. In one embodiment, the pharmaceutical composition is applied to the skin or mucosal surface of the subject. The skin or mucosal surface may be intact or abraded.

[0017] Also included in the present application is a use of a topical ibuprofen composition of the application to treat pain.

[0018] The present application also includes a topical ibuprofen composition of the application for use to treat pain.

[0019] The compositions of the application are useful to alleviate acute pain, chronic pain, or both. Compositions of the application are particularly suited for use in treating acute pain due to minor strains, sprains and contusions. In an embodiment of the application the pain is associated with inflammation. In a further embodiment the pain is associated with osteoarthritis.

[0020] Other features and advantages of the present application will become apparent from the following detailed description. It should be

understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the application, are given by way of illustration only, since various changes and modifications within the spirit and scope of the application will become apparent to those skilled in the art from
5 this detailed description.

Brief description of the drawings

[0021] The embodiments of the application will now be described in greater detail with reference to the attached drawings in which:

10 **[0022]** Figure 1 is a bar graph showing the effect of thickening agents on the flux of compositions that represent embodiments of the present application. Reference is made to Table 3 for the identity and amounts of the components in the compositions.

15 **[0023]** Figure 2 is a bar graph showing the effect of various combinations of alcohols on the flux of compositions that represent embodiments of the present application. Reference is made to Table 4 for the identity and amounts of the components in the compositions.

[0024] Figure 3 is a bar graph showing the effect of terpenes on the flux of compositions that represent embodiments of the present application.
20 Reference is made to Table 5 for the identity and amounts of the components in the compositions.

[0025] Figure 4 is a bar graph showing the effect of additional solvents on the flux of compositions that represent embodiments of the present application. Reference is made to Table 6 for the identity and amounts of the
25 components in the compositions.

[0026] Figure 5 is a bar graph showing the effect of additional solvents on the flux of compositions that represent embodiments of the present application. Reference is made to Table 7 for the identity and amounts of the components in the compositions.

[0027] Figure 6 is a bar graph showing the effect of additional solvents on the flux of compositions that represent embodiments of the present application. Reference is made to Table 8 for the identity and amounts of the components in the compositions.

5 **[0028]** Figure 7 is a bar graph showing the flux of modified thickened formulations that represent embodiments of the present application. Reference is made to Table 10 for the identity and amounts of the components in the compositions.

[0029] Figure 8 is a bar graph showing the effect of pH on the flux of
10 compositions that represent embodiments of the present application. Reference is made to Table 12 for the identity and amounts of the components in the compositions.

[0030] Figure 9 is a bar graph showing the effect of lactic acid levels in citrate buffer on the flux of compositions that represent embodiments of the
15 present application. Reference is made to Table 13 for the identity and amounts of the components in the compositions.

[0031] Figure 10 is a bar graph showing the flux of compositions that have not been pH adjusted that represent embodiments of the present application. Reference is made to Table 15 for the identity and amounts of
20 the components in the compositions.

[0032] Figure 11 is a bar graph showing the effect of buffer-adjusted pH (~pH 4.2) on the flux of compositions that represent embodiments of the present application. Reference is made to Table 16 for the identity and amounts of the components in the compositions.

25 **[0033]** Figure 12 is a bar graph showing the effect of pH and buffers on the flux of compositions that represent embodiments of the present application. Reference is made to Table 17 for the identity and amounts of the components in the compositions.

[0034] Figure 13 is a bar graph showing the effect of percent
30 ingredients on the flux of compositions that represent embodiments of the

present application. Reference is made to Table 21 for the identity and amounts of the components in the compositions.


Detailed description of the Application

I. Definitions

- 5 [0035] Unless otherwise indicated, the definitions and embodiments described in this and other sections are intended to be applicable to all embodiments and aspects of the application herein described for which they are suitable as would be understood by a person skilled in the art.
- [0036] The terms "a," "an," or "the" as used herein not only include
10 aspects with one member, but also includes aspects with more than one member. For example, an embodiment including "a surfactant" should be understood to present certain embodiments with one surfactant or certain embodiment with two or more additional surfactants.
- [0037] Terms of degree such as "about", "approximately" and
15 "substantially" as used herein mean a reasonable amount of deviation of the modified term such that the end result is not significantly changed. These terms of degree should be construed as including a deviation of at least $\pm 5\%$ of the modified term if this deviation would not negate the meaning of the word it modifies.
- 20 [0038] In compositions comprising an "additional" or "second" component, the second component as used herein is chemically different from the other components or first component. A "third" component is different from the other, first, and second components, and further enumerated or "additional" components are similarly different.
- 25 [0039] As used herein, unless otherwise noted, the term "anti-solvent" refers to a solvent which does not dissolve a specific substance and is added to a solution of said substance, directly or by vapor diffusion, to cause precipitation of said substance.
- [0040] The term "agent" as used herein indicates a compound or
30 mixture of compounds that, when added to a composition, tend to produce a

particular effect on the composition's properties. For example, a composition comprising a thickening agent is likely to be more viscous than an otherwise identical comparative composition that lacks the thickening agent.

[0041] The term "C₁₋₄alcohol ester of citric acid" as used herein means
5 a compound of the formula:



wherein at least one, two, three or four, of R^a, R^b, R^c and R^d are
10 simultaneously or independently straight or branched chain C₁₋₄alkyl, the remainder of R^a, R^b, R^c and R^d being H.

[0042] "Cellulosic thickening agent" as used herein includes a thickening agent that is a natural or synthetic polymeric carbohydrate (e.g., cellulose and pharmaceutically acceptable vegetable gums) or a polymeric or
15 oligomeric derivative of a polymeric carbohydrate that is produced by chemical modification (e.g., hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose). Representative cellulosic thickening agents include cellulose, hydroxypropyl cellulose ("HPC"), hydroxypropyl methyl cellulose ("HPMC"), hydroxyethyl cellulose ("HEC"), methyl cellulose,
20 carboxymethyl cellulose, and the like.

[0043] In general, chiral compounds described herein (e.g., lactic acid), include the racemic form or the D- or the L- enantiomer thereof (e.g., D-lactic acid or L-lactic acid).

[0044] In understanding the scope of the present disclosure, the term
25 "comprising" and its derivatives, as used herein, are intended to be open ended terms that specify the presence of the stated features, elements, components, groups, integers, and/or steps, but do not exclude the presence

of other unstated features, elements, components, groups, integers and/or steps. The foregoing also applies to words having similar meanings such as the terms, "including", "having" and their derivatives. The term "consisting" and its derivatives, as used herein, are intended to be closed terms that
5 specify the presence of the stated features, elements, components, groups, integers, and/or steps, but exclude the presence of other unstated features, elements, components, groups, integers and/or steps. The term "consisting essentially of", as used herein, is intended to specify the presence of the stated features, elements, components, groups, integers, and/or steps as well
10 as those that do not materially affect the basic and novel characteristic(s) of features, elements, components, groups, integers, and/or steps.

[0045] "Enhancement ratio" ("ER") as used herein is the ratio of a test result (e.g., $\mu\text{g}/\text{cm}^2$ accumulated dose of product) from a formulation comprising ibuprofen to the corresponding test result from a control
15 composition comprising ibuprofen at the same concentration in the formulation.

[0046] As used herein, the phrase "effective amount" means an amount sufficient to achieve the desired result and accordingly will depend on the ingredient and its desired result. Nonetheless, once the desired effect is
20 known, determining the effective amount is within the skill of a person skilled in the art.

[0047] In general, the "error bars" on the graphs represent the standard error of the mean value, whereas the top of the solid, shaded bar represents a single data value, which is the mean value of the distribution of data values.

25 **[0048]** "Finite dosing" as used herein generally includes an application of a limited reservoir of an active agent. The active agent in the reservoir is depleted with time, leading to a decrease of the absorption rate of the active agent after a maximum absorption rate is reached.

- [0049]** “Formulation,” “pharmaceutical composition,” and “composition” as used herein are equivalent terms referring to a composition of matter for pharmaceutical use.
- [0050]** The term “hydroalcoholic” means a chassis or base solvent system that comprises a combination of water and one or more alcohols.
- [0051]** “Infinite dosing” as used herein generally includes an application of a large reservoir of an active agent. The active agent in the reservoir is not significantly depleted with time, thereby providing protracted, continuous, steady-state absorption of the active.
- [0052]** “Lower alcohol” as used herein includes straight- or branched-chain alkyl alcohols comprising 1, 2, 3, 4, 5 or 6 carbon atoms. Representative lower alcohols include methanol, ethanol, n-propanol, isopropanol, n-butanol, t-butanol, n-pentanol, 3-pentanol, 2-methoxyethanol, propylene glycol and the like.
- [0053]** “Monohydric alcohol” as used herein includes straight- or branched-chain alkyl alcohols with a single hydroxyl group. Representative monohydric alcohols include methanol, ethanol, n-propanol, isopropanol, n-butanol, t-butanol, n-pentanol, 3-pentanol, 2-methoxyethanol, 2-(2-ethoxyethoxy)ethanol, olelyl alcohol and the like.
- [0054]** “Penetration enhancer”, “molecular penetration enhancer” or “MPE™” as used herein includes an agent or a combination of agents that improves the transport of molecules such as a pharmaceutically or cosmetically active agent into or through a natural membrane such as skin or nail. Various conditions may occur at different sites in the body, either in the skin or below the skin, creating a need to target delivery of compounds. For example, in a treatment for osteoarthritis, delivery of the active agent to the underlying tissues surrounding the joint may be necessary to achieve therapeutic benefit. A molecular penetration enhancer may be used to assist in the delivery of an active agent i) directly into the skin or nail; ii) locally, or regionally, into tissue(s) underlying the skin or nail; or iii) indirectly via

systemic distribution to the site of the disease. If systemic distribution of an active agent (e.g., ibuprofen) would be likely to produce side effects, a molecular penetration enhancer is preferably selected to maximize direct delivery and to minimize systemic distribution. A molecular penetration enhancer may be a pure substance or may comprise, consist essentially of, or consist of a mixture of different chemical entities.

[0055] Generally, when a percentage range is defined, it incorporates all full or partial percentages in between (i.e., within the bounds of the range). For example, a percentage range of 15 to 25% would also include *inter alia* the specific values of 17.36% and 21%. A percentage range of about 13% to 17% would also include *inter alia* the specific values of 12.97%, 16%, and 17.1%.

[0056] The term "pH adjusting agent" as used herein refers to a compound added to the compositions of the present application for the purpose of changing the pH of the solution. Examples of such agents include pharmaceutically acceptable acids, pharmaceutically acceptable bases, and/or pharmaceutically acceptable buffers.

[0057] The term "pharmaceutically acceptable" means compatible with the treatment of animals, in particular, humans.

[0058] The term "pharmaceutically acceptable salt" means a pharmaceutically acceptable acid addition salt or a pharmaceutically acceptable basic addition salt. The formation of a desired compound salt is achieved using standard techniques. For example, the neutral compound is treated with an acid or base in a suitable solvent and the formed salt is isolated by filtration, extraction or any other suitable method.

[0059] The term "pharmaceutically acceptable acid addition salt" as used herein means a pharmaceutically acceptable salt of a basic compound. Basic compounds that form an acid addition salt include, for example, compounds comprising an amine group. Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulfuric and phosphoric

acids. Illustrative organic acids that form suitable salts include mono-, di-, and tricarboxylic acids such as glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, benzoic, phenylacetic, cinnamic and salicylic acids, as well as sulfonic acids such as p-toluene sulfonic and methanesulfonic acids. Either the mono (such as monohydrogen orthophosphate or hydrogen sulfate) or di-acid salts can be formed, and such salts may exist in either a hydrated, solvated or substantially anhydrous form. In general, acid addition salts are more soluble in water and various hydrophilic organic solvents, and generally demonstrate higher melting points in comparison to their free base forms. The selection of an appropriate salt will be known to one skilled in the art.

[0060] The term “pharmaceutically acceptable basic addition salt” as used herein means a pharmaceutically acceptable organic or inorganic base addition salt of an acidic compound. Acidic compounds that form a basic addition salt include, for example, compounds comprising a carboxylic acid group. Illustrative inorganic bases which form suitable salts include lithium, sodium, potassium, calcium, magnesium or barium hydroxide. Illustrative organic bases which form suitable salts include aliphatic, alicyclic or aromatic organic amines such as methylamine, trimethylamine and picoline, alkylammonias (such as tetraalkylammonias) or ammonia. The selection of an appropriate salt will be known to a person skilled in the art.

[0061] “Ratio”, as it pertains to comparative flux values described herein, are calculated based on the cumulative amount of active (e.g. ibuprofen) delivered through the skin over a period of 4-60 hrs, preferably 24 hrs.

[0062] The term “solvate” as used herein means a compound or its pharmaceutically acceptable salt, wherein molecules of a suitable solvent are incorporated in the crystal lattice. A suitable solvent is pharmaceutically acceptable at the dosage administered. Examples of suitable solvents are ethanol, water and the like. When water is the solvent, the compound is referred to as a “hydrate”. The formation of solvates will vary depending on

the compound and the solvate. In general, solvates are formed by dissolving the compound in the suitable solvent and isolating the solvate by cooling or using an antisolvent. The solvate is typically dried or azeotroped under ambient conditions.

5 **[0063]** Where compounds possess more than one or more asymmetric centre, they may exist as "stereoisomers", such as enantiomers and diastereomers. It is to be understood that all such stereoisomers and mixtures thereof in any proportion are encompassed within the scope of the present application. It is to be understood that while the stereochemistry of
10 compounds may be as provided for in any given compound shown herein, such compounds may also contain certain amounts (e.g. less than 20%, less than 15%, less than 10%, less than 5% or less than 1%) of compounds having alternate stereochemistry.

[0064] The term "subject" as used herein includes all members of the
15 animal kingdom, including mammals, and suitably refers to humans.

[0065] "Thickening agent" as used herein includes an agent or combination of agents that increases the viscosity of a composition. A thickening agent may be a pure substance, or it may comprise, consist essentially of, or consist of a mixture of different chemical entities. Exemplary
20 thickening agents include cellulose polymers, carbomer polymers, carbomer derivatives, cellulose derivatives, polyvinyl alcohol, poloxamers, polysaccharides, and the like, as well as mixtures thereof.

[0066] "Topical formulation" as used herein includes a composition that is suitable for topical application to the skin, nail, or mucosa. A topical
25 formulation may, for example, be used to confer a therapeutic or cosmetic benefit to its user. Specific topical formulations can be used for local, regional, or transdermal application of substances.

[0067] "Transdermal" as used herein includes a process that occurs through the skin. The terms "transdermal," "percutaneous" and


“transcutaneous” can be used interchangeably. In certain embodiments, “transdermal” also includes epicutaneous.

[0068] “Transdermal application” as used herein includes administration through the skin. Transdermal application can be used for systemic delivery of an active agent; however, it is also useful for delivery of an active agent to tissues underlying the skin with minimal systemic absorption. In certain embodiments, “transdermal application” can also include epicutaneous application.

[0069] The term “treating” or “treatment” as used herein and as is well understood in the art, means an approach for obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilizing (i.e. not worsening) the state of disease, prevention of disease spread, delaying or slowing of disease progression, amelioration or palliation of the disease state, diminishment of the reoccurrence of disease, and remission (whether partial or total), whether detectable or undetectable. “Treating” and “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment. “Treating” and “treatment” as used herein also include prophylactic treatment. Treatment methods comprise administering to a subject a therapeutically effective amount of an active agent and optionally consists of a single administration, or alternatively comprises a series of applications. The length of the treatment period depends on a variety of factors, such as the severity of the condition, the age of the patient, the concentration, the activity of the compositions described herein, and/or a combination thereof. It will also be appreciated that the effective dosage of an agent used for the treatment or prophylaxis may increase or decrease over the course of a particular treatment or prophylaxis regime. Changes in dosage may result and become apparent by standard diagnostic assays known in the art. In some instances, chronic administration may be required. For example,

the compositions are administered to the subject in an amount and for a duration sufficient to treat the patient.

[0070] “Triethyl citrate” as used herein means the compound of the formula:



5

[0071] In general, the unit prefix “u” as used herein is equivalent to “μ” or “micro.” For example, “ul” is equivalent to “μl” or “microliters.”

[0072] The term “water” as used herein as an ingredient in the compositions of the application refers to pharmaceutically acceptable water.

10 **[0073]** The term “w/w” or “wt/wt” means a percentage expressed in terms of weight of the ingredient or agent over the total weight of the composition multiplied by 100.

II. Compositions

[0074] The present application includes a composition comprising
 15 ibuprofen, a hydroalcoholic-based solvent, C₁₋₄alcohol ester of citric acid and a surfactant, wherein the composition is formulated for topical administration. In an embodiment that composition is a pharmaceutical composition for human or veterinary use.

(a) Ibuprofen

20 **[0075]** The present application includes compositions comprising ibuprofen. In an embodiment, the compositions comprise a therapeutically effective amount of ibuprofen. In a further embodiment the compositions comprise a therapeutically effective amount of ibuprofen to treat pain. In another embodiment, the compositions of the present application comprise
 25 about 0.1% (w/w) to about 10% (w/w), about 0.5% (w/w) to about 9.0% (w/w), about 1.0% (w/w) to about 8.0% (w/w), about 2.0% (w/w) to about 7.0% (w/w),


about 3.0% (w/w) to about 6.5% (w/w), about 4.0% (w/w) to about 6.0% (w/w) or about 5% (w/w) of ibuprofen.

[0076] In one embodiment, a composition of the present application permits delivery of an ibuprofen daily dosage of about 0.01 mg to about 1200 mg, about 0.1 mg to about 400 mg, about 1 mg to about 370 mg, about 5 mg to about 350 mg, about 10 mg to about 325 mg, about 50 mg to about 300 mg, or about 100 mg to about 250 mg, in single or divides doses. In another embodiment, the concentration of ibuprofen is such that the dosage amount can be provided by application of the composition from one to four times a day, one to three times a day, or one to two times a day, to a skin area of up to about 2500 cm², suitably about 1200 to 1800 cm². Alternatively, the composition can be applied to a skin area of about 1 to 50 cm², about 50 to 250 cm², about 100 to 500 cm², about 200 to 800 cm², or about 800 to 1200 cm². A person skilled in the art will appreciate that the dosage and application area will vary on, and can be tailored to, the area being treated.

[0077] In an embodiment of the application, the ibuprofen is racemic (*R/S*) ibuprofen. In a further embodiment, the ibuprofen is (*S*)-ibuprofen. When the ibuprofen is used as an enantiomerically enriched substance, it is an embodiment that it also contain less than about 20%, less than about 15%, less than about 10%, less than about 5% or less than about 1% of the alternate enantiomer.

(b) C₁₋₄alcohol Ester of Citric acid

[0078] The present application includes compositions comprising a C₁₋₄alcohol ester of citric acid. In an embodiment of the application the C₁₋₄alcohol ester of citric acid is a compound of the formula:



wherein at least one, two, three or four, of R^a, R^b, R^c and R^d are simultaneously or independently straight or branched chain C₁₋₄alkyl, the remainder of R^a, R^b, R^c and R^d being H. In a further embodiment R^a, R^b and R^c are the same and are selected from methyl, ethyl, propyl, butyl, isopropyl, isobutyl and t-butyl and R^d is selected from H and methyl. In a further embodiment R^a, R^b and R^c are ethyl and R^d is H (i.e. triethyl citrate).

[0079] Without being bound by theory, the C₁₋₄alcohol ester of citric acid of the application may function to aid in the homogeneity of the composition. The C₁₋₄alcohol ester of citric acid of the application may additionally or alternatively function as a molecular penetration enhancer (MPE™).


[0080] In an embodiment, the compositions comprise an effective amount of a C₁₋₄alcohol ester of citric acid. In the absence of a C₁₋₄alcohol ester of citric acid, such as triethyl citrate, the compositions are not homogeneous and a slight reduction of permeation is observed. In an embodiment, the compositions comprise an amount of a C₁₋₄alcohol ester of citric acid (e.g. triethyl citrate) that is effective to improve the homogeneity and stability of the composition compared to an otherwise identical comparative composition that lacks a C₁₋₄alcohol ester of citric acid (e.g. triethyl citrate). In another embodiment, the compositions of the present application comprise about 0.5% (w/w) to about 5% (w/w), about 1.5% (w/w) to about 4.5% (w/w), about 2.0% (w/w) to about 4.0% (w/w) or about 3% (w/w) of the C₁₋₄alcohol ester of citric acid, for e.g. triethyl citrate.

(c) Surfactants

[0081] The present application includes compositions comprising at least one surfactant or surface active agent. In certain aspects, the surfactant may additionally or alternately function as a molecular penetration enhancer (MPE™).

[0082] In an embodiment the surfactant is an ionic surfactant such as an anionic surfactant or a zwitterionic (or amphoteric) surfactant or a mixture thereof. Examples of anionic surfactants include, for example, those

comprising a sulfate anion such as sodium lauryl sulfate, ammonium lauryl sulfate, sodium dodecyl sulfate and other alkyl sulfate salts, or mixtures thereof. Examples of zwitterionic surfactants include, for example, the *N*-(cocoalkyl) amidopropyl betaines having the general formula:



5

wherein R is an alkyl chain comprising 9, 11, or 13, suitably 11 carbon atoms. In one embodiment, the zwitterionic surfactant is the cocoamidopropyl betaine, {[3-(dodecanoylamino)propyl](dimethyl)ammonio}acetate (Amphosol®).

10 **[0083]** In an embodiment the surfactant is present in the compositions of the application in an effective amount. In a further embodiment, the effective amount is an amount that causes a decrease in precipitation in the composition compared to an otherwise identical comparative composition that lacks the surfactant.

15 **[0084]** In an embodiment, the compositions of the present application comprise about 0.5% (w/w) to about 20% (w/w), about 0.75% (w/w) to about 15% (w/w), about 1.0% (w/w) to about 10% (w/w), about 1.5% (w/w) to about 9% (w/w) or about 2.0% (w/w) to about 8.0% (w/w) of one or more surfactants.

20 **[0085]** In an embodiment of the application, the compositions comprise an anionic surfactant, for example sodium lauryl sulfate, as the only surfactant. When the compositions comprise sodium lauryl sulfate as the only surfactant, it is an embodiment that the composition comprises about 0.5% (w/w) to about 5% (w/w), about 1.0% (w/w) to about 4.0% (w/w), about 1.5% (w/w) to about 3.0% (w/w) or about 2% (w/w) of this surfactant.

25

[0086] In another embodiment of the application, the compositions comprise a zwitterionic surfactant, for example *N*-(cocoalkyl) amidopropyl betaines, as the only surfactant. When the compositions comprise *N*-

(cocoalkyl) amidopropyl betaines as the only surfactant, it is embodiment that the composition comprises about 1.0% (w/w) to about 10% (w/w), about 2.0% (w/w) to about 9.0% (w/w), about 3.0% (w/w) to about 8.0% (w/w) or about 4.0% (w/w) to about 6.0% (w/w) of this surfactant.

5 **[0087]** In another embodiment, the compositions of the present application comprise both an anionic and a zwitterionic surfactant, for example sodium lauryl sulfate and an N-(cocoalkyl) amidopropyl betaine. When the compositions comprise both an anionic and a zwitterionic surfactant, it is an embodiment that the composition comprises about 2.0%
10 (w/w) to about 10% (w/w), about 3.0% (w/w) to about 9.0% (w/w) or about 4.0% (w/w) to about 8.0% (w/w) of combined total surfactant. It is a further embodiment that the ratio of zwitterionic to anionic surfactant be about 10:1 to about 2:1 or about 4:1.

[0088] In certain embodiments the compositions of the present application further comprise a nonionic surfactant. Examples of nonionic
15 surfactants include, but are not limited to alkyl poly(ethylene oxide), poloxamers, alkyl polyglucosides, fatty alcohols, polysorbates, glycerine esters such as glycerin ricinoleate and glycerin monolaurate, and alkyl-poly(ethylene oxide) ethers (e.g. Brij™ surfactants), and mixtures thereof. Nonionic
20 surfactants can also act as emulsifiers. In an embodiment, the nonionic surfactant is present in the composition in an amount of about 0.1% (w/w) to about 20% (w/w), about 1.0% (w/w) to about 15% (w/w) or about 2.0% (w/w) to about 10.0% (w/w).

[0089] When the compositions further comprise a nonionic surfactant, it
25 is embodiment that the composition comprises about 0.5% (w/w) to about 20% (w/w), about 0.75% (w/w) to about 15% (w/w), about 1.0% (w/w) to about 10% (w/w), about 2.0% (w/w) to about 9.0% (w/w), about 3.0% (w/w) to about 8.0% (w/w) or about 4.0% (w/w) to about 6.0% (w/w) of combined total surfactant.

(d) Solvents

[0090] The compositions of the present application are based on a hydroalcoholic chassis, and therefore comprise, as the main solvent, a mixture of water and an alcohol. It is an embodiment of the present application that the compositions comprise about 10% (w/w) to about 60% (w/w), about 15% (w/w) to about 55% (w/w) or about 20% (w/w) to about 50% (w/w) of water and about 10% (w/w) to about 60% (w/w), about 15% (w/w) to about 55% (w/w) or about 20% (w/w) to about 50% (w/w) of alcohol.

[0091] In an embodiment, the water component of the hydroalcoholic chassis is buffered. Alternately or additionally, the water component is adjusted with a pH adjusting agent.

[0092] In an embodiment, the alcohol is a lower alkyl alcohol or a mixture of lower alkyl alcohols. In a further embodiment, the alcohol is a monohydric alcohol. In a further embodiment, the alcohol is ethanol, isopropanol, or 2-(2-ethoxyethoxy)ethanol (transcutol), or a mixture thereof.

[0093] In another embodiment, the lower alcohol is a diol, or a mixture thereof. Alternatively, the composition additionally comprises a diol. Suitable diols include, but are not limited to, propylene glycol, butanediol, butynediol, pentanediol, hexanediol, octanediol, neopentyl glycol, 2-methyl-1,3-propanediol, diethylene glycol, triethylene glycol, tetraethylene glycol, dipropylene glycol and dibutylene glycol, and mixtures thereof. In an embodiment, the diol is propylene glycol. In one embodiment, the formulation comprises about 0% (w/w) to about 20% (w/w), about 1.0% (w/w) to about 15% (w/w) or about 4% (w/w) to about 15% (w/w) of propylene glycol.

[0094] In a further embodiment of the application, the composition further comprises additional solvents. Examples of suitable additional solvents include, but are not limited to, D-panthenol, dimethylsulfoxide (DMSO) and dimethylacetamide (DMA), and mixtures thereof. When additional solvents are included in the compositions of the present application, it is an embodiment that they are present in an amount of about 0% (w/w) to

about 20% (w/w), about 1.0% (w/w) to about 15% (w/w) or about 4% (w/w) to about 15% (w/w).

[0095] Without being bound by theory, it is a further aspect of the application that the solvent can additionally or alternately function as a
5 molecular penetration enhancer (MPE™).

(e) Other ingredients

[0096] The compositions of the present application further include at least one other pharmaceutically acceptable agent or excipient.

[0097] In an embodiment, the compositions of the present application
10 include a pH adjusting agent. In a further embodiment, the pH adjusting agent is present in an effective amount. In an embodiment, the pH adjusting agent adjusts the pH so that ibuprofen is in a protonated form. Accordingly the pH adjusting agent is present in an amount effective to keep ibuprofen in a protonated form.

[0098] In one particular embodiment, the pH-adjusting agent is a base. Suitable pH-adjusting bases include bicarbonates, carbonates, hydroxides (such as ammonium hydroxide, alkali or alkaline earth metal hydroxides as well as transition metal hydroxides), and the like. In an alternative aspect, suitable pH-adjusting bases include amines, such as diethanolamine,
20 triethanolamine, or aminopropanol. Additionally or alternatively, the pH-adjusting agent can be an acid, an acid salt, or mixtures thereof. In an embodiment, the pH-adjusting agent comprises two agents (e.g., sodium hydroxide and hydrochloric acid) that are included as needed to adjust the final pH of the composition to a desired pH.

[0099] In an embodiment, the pH adjusting agent is lactic acid. In an further embodiment, the composition comprises about 0.1% (w/w) to about 5% (w/w), about 0.25% (w/w) to about 4% (w/w), about 0.5% (w/w) to about 3.0% (w/w), about 0.75% (w/w) to about 2.0% (w/w) or about 1.0% (w/w) of a pH adjusting agent, suitably lactic acid.

[00100] In certain aspects, the lactic acid is racemic (*i.e.*, racemic lactic acid). Alternatively, the lactic acid is enantiomerically enriched or is substantially a single enantiomer (*e.g.*, (*S*)-lactic acid, also termed L-lactic acid). In an embodiment, the lactic acid is L-lactic acid. In other
5 embodiments, the lactic acid additionally or alternatively functions as a molecular penetration enhancer (MPE™).

[00101] Other pH adjusting agents can also be used, including other acid, acid salts, or mixtures thereof. Further, the pH adjusting agent can additionally or alternately be a buffer. Suitable buffers include citrate/citric
10 acid buffers, acetate/acetic acid buffers, phosphate/phosphoric acid buffers, formate/formic acid buffers, propionate/propionic acid buffers, lactate/lactic acid buffers, carbonate/carbonic acid buffers and the like. In one embodiment, the buffer is phosphate buffered saline (PBS). In an alternate embodiment, the buffer is a citrate buffer. In a further embodiment, the buffer comprises or
15 is included in the water component of the hydroalcoholic chassis.

[00102] In an embodiment, the inventive formulation includes a buffer, and a second pH-adjusting agent (*e.g.*, sodium hydroxide or hydrochloric acid) to adjust the pH of the composition to a desired pH. More preferably, the second pH-adjusting agent comprises two agents (*e.g.*, sodium hydroxide
20 and hydrochloric acid) that are included as needed to adjust the pH of the hydroalcoholic chassis and/or final composition to a desired pH.

[00103] In an embodiment, the compositions of the present application comprise at least one thickening agent, for example, a cellulosic thickening agent. The addition of thickeners did not cause a direct effect on the
25 ibuprofen flux but provided a more viscous composition that is suitable for gel topical formulations. Suitable cellulosic thickening agents include, but are not limited to, hydroxypropyl cellulose (HPC) of various grades, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hydroxyethyl methyl cellulose, ethyl cellulose, methyl cellulose, carboxymethyl cellulose, dextran, guar gum,
30 pectin, starch, cellulose, and the like, and mixtures thereof. In an embodiment, the cellulosic thickening agent is HPC.

[00104] In a further embodiment, the composition comprises about 0.0% (w/w) to about 5% (w/w), about 0.1% (w/w) to about 4% (w/w), about 0.5% (w/w) to about 3.0% (w/w), about 0.75% (w/w) to about 2.0% (w/w) or about 1.0% (w/w) of a thickening agent, suitably a cellulose thickening agent.

5 **[00105]** In another embodiment, the compositions of the present application further comprise a humectant, emollient and/or a moisturizer. An example of such a compound is D-panthenol. The addition of D-panthenol also reduces precipitation. In an embodiment the compositions of the present application comprise 0.0% (w/w) to about 10% (w/w), about 1.0% (w/w) to
10 about 9% (w/w), about 2.0% (w/w) to about 8.0% (w/w), about 3.0% (w/w) to about 7.0% (w/w), about 4.0% (w/w) to about 6.0% (w/w) or about 5% (w/w) of D-panthenol.

[00106] In another embodiment, the compositions of the present application additionally comprise a terpene. In a further embodiment the
15 terpene is a monoterpene such as limonene or α -terpineol, or a mixture thereof. In certain embodiments the presence of one or more terpenes in the compositions enhance the activity of the composition. As such, the terpene may function as an MPE™. In a further embodiment, the one or more terpenes are present in the composition in an amount of about 0.0% (w/w) to
20 about 10% (w/w), about 1.0% (w/w) to about 9% (w/w), about 2.0% (w/w) to about 8.0% (w/w), about 3.0% (w/w) to about 7.0% (w/w), about 4.0% (w/w) to about 6.0% (w/w) or about 5% (w/w).

[00107] In certain embodiments, urea is added to the compositions of the present application. In a further embodiment, urea is present in the
25 composition in an amount of about 0.0% (w/w) to about 10% (w/w), about 1.0% (w/w) to about 9% (w/w), about 2.0% (w/w) to about 8.0% (w/w), about 3.0% (w/w) to about 7.0% (w/w), about 4.0% (w/w) to about 6.0% (w/w) or about 5% (w/w).

[00108] In a further embodiment, the compositions of the present
30 application additionally comprises an anti-oxidant. Suitable anti-oxidants for use in the present invention include, but are not limited to, butylated

hydroxytoluene, butylated hydroxyanisole, ascorbyl linoleate, ascorbyl dipalmitate, ascorbyl tocopherol maleate, calcium ascorbate, carotenoids, kojic acid and its pharmaceutically acceptable salts, thioglycolic acid and its pharmaceutically acceptable salts (e.g., ammonium salts), tocopherol, 5 tocopherol acetate, tocophereth-5, tocophereth-12, tocophereth-18, tocophereth-80 and the like, and mixtures thereof.

[00109] In still another embodiment, the composition additionally comprises a chelating agent. Suitable chelating agents include, but are not limited to, ethylenediamine tetraacetic acid (EDTA), diammonium EDTA, 10 dipotassium EDTA, calcium disodium EDTA, H-EDTA, TEA-EDTA, tetrasodium EDTA, tripotassium EDTA, trisodium phosphate, diammonium citrate, galactaric acid, galacturonic acid, gluconic acid, glucuronic acid, humic acid, cyclodextrin, potassium citrate, the potassium salt of ethylenediamine-tetra (methylene phosphonic acid) (EDTMP), sodium citrate, sodium EDTMP, 15 and the like, and mixtures thereof.

[00110] In yet another embodiment, the composition additionally comprises a preservative, such as propyl paraben or methyl paraben, or combinations thereof. The formulation may be made bacteriostatic by the addition of preservatives. For example, a composition can contain about 20 0.001 to 8%, about 0.01 to 6%, or about 0.05 to 5% (w/w) of a preservative or a combination of preservatives. A variety of preservatives are suitable, including, but not limited to, benzoic acid, benzyl alcohol, benzylhemiformal, benzylparaben, 5-bromo-5-nitro-1,3-dioxane, 2-bromo-2-nitropropane-1,3-diol, butyl paraben, phenoxyethanol, methyl paraben, propyl paraben, diazolidinyl 25 urea, calcium benzoate, calcium propionate, captan, chlorhexidine diacetate, chlorhexidine digluconate, chlorhexidine dihydrochloride, chloroacetamide, chlorobutanol, p-chloro-m-cresol, chlorophene, chlorothymol, chloroxylenol, m-cresol, o-cresol, diethylene glycol dimethyl ether ("DEDM") hydantoin, DEDM hydantoin dilaurate, dehydroacetic acid, dibromopropamide 30 diisethionate, and 1,3-bis(hydroxymethyl)-5,5-dimethylimidazolidine-2,4-dione ("DMDM") hydantoin, and mixtures thereof.

(f) Other properties

[00111] In still yet another embodiment of the present application, the composition is selected from a spray, a gel, a cream, an emulsion, a microemulsion, a lotion, an organogel, an ointment, a solution (e.g., a moderate to highly viscous solution), and a transdermal patch. In a further embodiment, the composition is a gel, for example, a low-viscosity gel, or a spray.

[00112] In certain other embodiments, the composition is designed for high penetration, for high retention in the skin, or for both high penetration and high retention. The optimal composition will have a balance between penetration and retention, enabling an effective amount of the active ingredient to pass through the skin, but also enabling it to stay in the target area for a sufficient duration to alleviate the patient's pain or other symptoms.

[00113] In another embodiment, the composition is designed for topical efficacy with minimal systemic distribution of the active through the body by the circulatory system (e.g., the cardiovascular system). The optimal composition will have low systemic bioavailability, but will effectively treat pain or other symptoms associated with the site of application.

[00114] In yet another embodiment, the composition of the present application has a flux (as determined by the finite dosing Franz cell procedure of Example 2) equal to or greater than the flux of a known comparative composition. Suitably, the flux is greater than the flux of a comparative composition. Suitably, the flux is at least 1.5 times greater than the comparative composition's flux. In other words the ratio of (i) the composition of the present application's ibuprofen flux to (ii) the comparative composition's flux is suitably greater than 1.0, and more suitably greater than 1.5.

[00115] In a further embodiment, the composition of the present application has an ibuprofen flux that is at least 2.0, 3.0 or 4.0 times greater than the ibuprofen flux of the comparative composition.

[00116] In an embodiment, the comparative composition is a topical aqueous/alcoholic gel comprising ibuprofen (5% wt/wt), ethanol, carbomer, propylene glycol, diethylamine and purified water. An example of such a composition is Ibugel™ available from Dermal Laboratories in the United Kingdom.

[00117] In another alternative embodiment, the present application includes a solution formulation comprising ibuprofen and having a flux as determined by the multiple finite dosing Franz cell procedure (see Example 2) of at least 0.1 µg/hr/cm² at 24 hours or at least 0.2 µg/hr/cm² at 24 hours.

10 **[00118]** In still another embodiment, the composition comprising ibuprofen has an enhancement ratio (ER) of at least 1.5. In yet another embodiment, the composition comprising ibuprofen has an ER of at least 2.0. In still another embodiment, the composition comprising ibuprofen has an ER that is at least 2.5.

15 **[00119]** In still another embodiment, the formulation comprising ibuprofen provides additional advantages in comparison to previously described ibuprofen compositions. Such advantages may include one or more of the following: adhering well to the skin, spreading easily, drying more quickly, and showing greater *in vivo* absorption. In some more specific
20 embodiments, the drying rate of the formulation is less than 20 minutes.

[00120] In yet another embodiment, the composition of the present application is more viscous than water at standard temperature and pressure (STP). Alternatively, the composition has a kinematic viscosity of more than about 1 centistokes (cSt) or a dynamic viscosity of more than about 1
25 centipoise (cP). In certain embodiments, the dynamic viscosity of the composition is at most about 2, 3, 4, 5, 7, 10, 12, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 75, 80, 90, 100, 150, 200, 250, 500, 1000, 2000, 3000, 5000 or 10,000 cP at STP. In further embodiments, the dynamic viscosity is at most about 2, 3, 4, 5, 7, 10, 12, 15, 20, 25, 30, 35, 40, 45 or 50 cP at STP. In still
30 further embodiments, the dynamic viscosity is at most about 2, 3, 4, 5, 7, 10, 12, 15 or 20 cP at STP. In yet other embodiments, the composition is

thixotropic (*i.e.*, it decreases in viscosity upon being stirred or shaken). The composition's viscosity can be adjusted by the addition of a thickening agent, such as a cellulosic thickening agent, for example, hydroxypropyl cellulose, or other thickening agents, or mixtures thereof.

5 **[00121]** In another embodiment, the composition is acidic. In certain embodiments, the composition has a pH of below about 7.5, of below about 6.5, of below about 5.5, of below about 4.5, of below about 3.5, or of below about 2.5. In certain other embodiments, the pH of the composition ranges from about 1.5 to about 7, about 2 to about 7, about 3 to about 7, about 4 to
10 about 7, or about 5 to about 7, or is about 6.5.

[00122] In further embodiments, the composition remains stable for an acceptable time period between preparation and use when stored in a closed container at normal ambient temperature. In an embodiment, an "acceptable time period" is at least about 30 days, at least about six months, at least about
15 one year, or at least about two years.

[00123] In an alternative embodiment, the application provides a formulation that degrades by less than 1% over the course of 6 months at room temperature. In an embodiment, the rate of degradation is less than about 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, or less than 0.1 %, and all fractions
20 in between, over the course of six months at room temperature.

(g) Specific formulations

[00124] In an embodiment of the present application, there is included a pharmaceutical composition comprising, consisting essentially of or consisting of ibuprofen, ethanol, water, triethyl citrate, lactic acid and sodium lauryl
25 sulfate. Accordingly, the present application includes a pharmaceutical composition comprising, consisting essentially of or consisting of:

- (a) about 1% (w/w) to about 10% (w/w) ibuprofen;
- (b) about 40% (w/w) to about 50% (w/w) ethanol;
- (c) about 40% (w/w) to about 50% (w/w) water;
- 30 (d) about 2% (w/w) to about 5% (w/w) triethyl citrate;

- (e) about 0.5% (w/w) to about 2.5% (w/w) lactic acid; and
- (f) about 1% (w/w) to about 3% (w/w) sodium lauryl sulfate.

[00125] In another embodiment of the above composition, the ethanol is replaced with a mixture of alcohols. In a further embodiment the mixture of
5 alcohols comprises alcohols selected from ethanol, a polyglycol and transcutol. Accordingly, the present application also includes a pharmaceutical composition comprising, consisting essentially of or consisting of:

- (a) about 1% (w/w) to about 10% (w/w) ibuprofen;
- 10 (b) about 15% (w/w) to about 25% (w/w) ethanol;
- (c) about 10% (w/w) to about 20% (w/w) transcutol;
- (d) about 5% (w/w) to about 15% (w/w) propylene glycol;
- (e) about 25% (w/w) to about 45% (w/w) water;
- (f) about 1% (w/w) to about 5% (w/w) triethyl citrate;
- 15 (g) about 0.5% (w/w) to about 2.5% (w/w) lactic acid; and
- (h) about 1% (w/w) to about 3% (w/w) sodium lauryl sulfate.

[00126] In another embodiment of the present application, there is included a pharmaceutical composition comprising, consisting essentially of or
20 consisting of ibuprofen, ethanol, water, triethyl citrate, lactic acid, propylene glycol, *N*-(cocoalkyl) amidopropyl betaine and sodium lauryl sulfate. Accordingly, the present application also includes a pharmaceutical composition comprising, consisting essentially of or consisting of:

- (a) about 1% (w/w) to about 10% (w/w) ibuprofen;
- 25 (b) about 25% (w/w) to about 35% (w/w) ethanol;
- (c) about 10% (w/w) to about 20% (w/w) propylene glycol;
- (d) about 35% (w/w) to about 45% (w/w) water;
- (e) about 2% (w/w) to about 5% (w/w) triethyl citrate;
- (f) about 0.5% (w/w) to about 2.5% (w/w) lactic acid;
- 30 (g) about 1% (w/w) to about 3% (w/w) sodium lauryl sulfate; and
- (h) about 2% (w/w) to about 10% (w/w) *N*-(cocoalkyl) amidopropyl betaine.

[00127] In another embodiment of the present application, there is included a pharmaceutical composition comprising, consisting essentially of or consisting of ibuprofen, ethanol, water, triethyl citrate, lactic acid, transcitol, propylene glycol and *N*-(cocoalkyl) amidopropyl betaine. Accordingly, the present application also includes a pharmaceutical composition comprising, consisting essentially of or consisting of:

- (a) about 1% (w/w) to about 10% (w/w) ibuprofen;
- (b) about 25% (w/w) to about 35% (w/w) ethanol;
- (c) about 15% (w/w) to about 25% (w/w) transcitol;
- (d) about 1% (w/w) to about 10% (w/w) propylene glycol;
- (e) about 25% (w/w) to about 35% (w/w) water;
- (f) about 2% (w/w) to about 5% (w/w) triethyl citrate;
- (g) about 0.5% (w/w) to about 2.5% (w/w) lactic acid; and
- (i) about 2% (w/w) to about 10% (w/w) *N*-(cocoalkyl) amidopropyl betaine.

[00128] In another embodiment of the present application, there is included a pharmaceutical composition comprising, consisting essentially of or consisting of ibuprofen, ethanol, water, triethyl citrate, lactic acid, DMSO and *N*-(cocoalkyl) amidopropyl betaine. Accordingly, the present application also includes a pharmaceutical composition comprising, consisting essentially of or consisting of:

- (a) about 1% (w/w) to about 10% (w/w) ibuprofen;
- (b) about 30% (w/w) to about 40% (w/w) ethanol;
- (c) about 35% (w/w) to about 45% (w/w) water;
- (d) about 2% (w/w) to about 5% (w/w) triethyl citrate;
- (e) about 0.5% (w/w) to about 2.5% (w/w) lactic acid;
- (f) about 2% (w/w) to about 10% (w/w) *N*-(cocoalkyl) amidopropyl betaine; and
- (g) about 5% (w/w) to about 15% (w/w) DMSO.

[00129] In another embodiment of the present application, the water component of the hydroalcoholic chassis is buffered and, is optionally

adjusted with a pH adjusting agent to a pH of about 6.5. Accordingly, there is included in the present application, a pharmaceutical composition comprising, consisting essentially of or consisting of ibuprofen, ethanol, phosphate buffered saline (PBS), triethyl citrate, lactic acid, propylene glycol, amphosol
5 and transcitol, wherein the pH is adjusted to about 6.5. In an embodiment, the present application includes a pharmaceutical composition comprising, consisting essentially of or consisting of:

- (a) about 1% (w/w) to about 10% (w/w) ibuprofen;
 - (b) about 25% (w/w) to about 35% (w/w) ethanol;
 - 10 (c) about 15% (w/w) to about 25% (w/w) transcitol;
 - (d) about 1% (w/w) to about 10% (w/w) propylene glycol;
 - (e) about 25% (w/w) to about 35% (w/w) PBS;
 - (f) about 1% (w/w) to about 5% (w/w) triethyl citrate;
 - (g) about 0.5% (w/w) to about 2.5% (w/w) lactic acid; and
 - 15 (i) about 2% (w/w) to about 10% (w/w) amphosol,
- wherein the pH is adjusted to about 6.5

[00130] In a further embodiment of the present application all compositions additionally comprise a cellulosic thickening agent, for example HPC, in an amount of about 0.5% (w/w) to about 5.0% (w/w), about 0.5%
20 (w/w) to about 3.0% (w/w), about 0.5% (w/w) to about 2.0% (w/w), or about 1.5% (w/w) to about 2.5% (w/w).

[00131] In a further embodiment of the present application all compositions additionally comprise at least one preservative, for example methyl paraben and/or propyl paraben, in an amount of about 0.1% (w/w) to
25 about 5.0% (w/w), about 0.1% (w/w) to about 3.0% (w/w) or about 0.1% (w/w) to about 1.0% (w/w).

III. Methods of preparation

[00132] In embodiments of the present application, the pharmaceutical compositions are formulated as a spray, cream, an emulsion, a
30 microemulsion, a gel (e.g., a hydrogel, an organogel, an inorganic or silica gel, a high-viscosity gel or a low-viscosity gel), a lotion, a lacquer, an

ointment, a solution (e.g., a moderate to highly viscous solution), or a transdermal patch. In a suitable embodiment, the composition is a gel, for example, a low-viscosity gel or a spray. Alternatively, the composition is a high-viscosity gel. The pharmaceutical composition of the present application
5 may also be formulated as a transdermal patch. Low viscosity gels are, for example, gels having a dynamic viscosity in the range of about 400-4000 cP at STP. High viscosity gels are, for example, gels having a dynamic viscosity of at least 4000 cP at STP.

[00133] Methods of preparing compositions for topical administration are
10 known in the art (see, for example, Remington's Pharmaceutical Sciences, 2000 - 20th edition, and The United States Pharmacopeia: The National Formulary, USP 24 NF19, published in 1999). In the present application all compositions are based on a hydroalcoholic chassis therefore alcohol-soluble components are dissolved in the alcohol and water soluble components are
15 dissolved in the water and the two solutions, once homogeneous, are slowly mixed to homogeneity.

IV: Methods of treatment

[00134] In certain embodiments, the present application includes a method for treating pain comprising applying an effective amount of a topical
20 ibuprofen composition of the application to a subject in need thereof. In one embodiment, the pharmaceutical composition is applied to the skin of the subject.

[00135] Also included in the present application is a use of a topical ibuprofen composition of the application to treat pain as well as a topical
25 ibuprofen composition of the application for use to treat pain.

[00136] In another embodiment of the present application, ibuprofen is delivered locally to the skin with minimal systemic absorption. In yet another embodiment, ibuprofen is delivered to and through the skin with minimal systemic absorption. In a still yet another embodiment, ibuprofen is delivered
30 to the tissue surrounding or under the area of skin application with minimal systemic absorption.

[00137] In other embodiments, the ibuprofen is delivered to a human or a non-human mammal.

[00138] The compositions of the application are useful to alleviate acute pain, chronic pain, or both. Compositions of the application are particularly suited for use in treating acute pain due to minor strains, sprains and contusions. In an embodiment of the application the pain is associated with inflammation. In a further embodiment the pain is associated with osteoarthritis. In another embodiment, the compositions of the present application are useful for the treatment of other chronic joint diseases characterized by joint pain, degeneration of articular cartilage, impaired movement, and stiffness. Suitable joints include, for example, the knee, elbow, hand, wrist and hip. In a further embodiment of the present application, the compositions of the application are useful for the treatment of other pain-associated disorders, including (but not limited to) muscle pain, lower back pain, neck pain, rheumatoid arthritis, tendonitis, fibromyalgia, myofascial pain, Carpal tunnel syndrome, gout and neuropathic pain conditions.

[00139] Due to the properties of higher flux and greater *in vivo* absorption, it is believed that the compositions of the present application can be administered at lower dosing (i.e. less frequent) than previously described ibuprofen formulations having the same concentration. In particular, it is expected that the compositions of the application can be used at three times a day dosing, twice a day dosing or once a day dosing.

[00140] Compositions of the present application may, if desired, be presented in a bottle, jar, sachet, or other container-closure system approved by government regulatory agencies, which may contain one or more unit dosage forms containing the active ingredient.

[00141] In some aspects, the compositions of the present invention are dispensed from a reservoir using a release assembly (e.g., a pump head) to dispense an amount of the composition whenever the release assembly is put into action. The enclosure may, for example, comprise an airless pump bottle

with a pump head. The amount of the composition dispensed by the pump may or may not be metered to dispense a consistent amount of formulation.

[00142] The package or dispenser may also be accompanied by a notice associated with the container in a form prescribed by a governmental agency
5 regulating the manufacture, use, or sale of pharmaceuticals, the notice indicating approval by the agency.

[00143] The following non-limiting examples are illustrative of the present application:

V. Examples

10 **Materials**

[00144] All materials used in the formulations of the present application were from commercial sources. Ibuprofen, USP was obtained from Spectrum Chemicals and Laboratory Products (New Brunswick, New Jersey, USA) or Arch Pharmalabs (India). Ibuprofen from Arch Pharmalabs had a smaller
15 average crystallite size and hence faster dissolution characteristics. Transcutol was obtained from Gattefosse Corporation, Paramus, New Jersey, USA. Triethyl citrate (FCC grade) was obtained from Spectrum Chemicals and Laboratory Products, New Brunswick, New Jersey, USA. DMSO was obtained from Gaylord Chemical Corporation, Slidell, LA, USA. D-Panthenol
20 and poloxamer 188 (Lutrol™ F 68) were obtained from BASF, Ludwigshafen, Germany. α -Terpineol was obtained from Alpha Aesar. Amphosol HCG was obtained from Stepan Company (Chicago, IL). Softigen™ was obtained from Sasol (Huls) America (Houston, TX). Glyceryl Monoricinoleate (GR) was obtained from Phoenix Chemical, Somerville, New Jersey, USA. Propylene
25 glycol was obtained from Riedel De Haen. D,L-Lactic acid was obtained from Mallinckrodt. Hydroxypropyl cellulose HY121 was obtained from Spetrum. Water was obtained from Thermo Scientific. All remaining chemicals were obtained from VWR, West Chester, Pennsylvania, USA, or Sigma Aldrich, St. Louis, Missouri, USA. Ibugel™ was obtained from Dermal Laboratories, UK.
30 Unless otherwise specified, the percentage specified is a weight/weight percentage.

Example 1: General Procedure for Formulation Preparation

[00145] For a typical composition of the present application, the ibuprofen was weighed into a suitable container and the alcohol, triethyl citrate and other solvents or agents were transferred quantitatively into the container and the resulting mixture was stirred using a suitable mixer until dissolution was complete. Lactic acid, was then added and mixing was continued. Water was then weighed into a separate container and the surfactants were added to the water and the resulting mixture was mixed until dissolution was complete. The aqueous surfactant portion was then added slowly to the alcohol portion and mixing was continued until dissolution was complete. Excessive stirring was avoided to prevent foaming.

[00146] The following representative formulations were prepared (refer to Table 1 for specific amounts of the components):

(a) Preparation of Ibuprofen formulation (IB 449)

15 **[00147]** 1- Weigh Ibuprofen in a suitable container.

[00148] 2- Quantitatively transfer ethanol, triethyl citrate, transcitol, and propylene glycol. Using a suitable mixer, mix until complete dissolution.

[00149] 3- Add lactic acid and mix well.

20 **[00150]** 4- In separate container weigh water and add sodium lauryl sulfate. Mix until complete dissolution.

[00151] 5- Slowly add item from step 4 to item from step 3. Mix until complete dissolution. Avoid excessive stirring to prevent foaming.

(b) Preparation of Ibuprofen formulations (IB 449a and 449b)

[00152] 1- Weigh Ibuprofen in a suitable container.

25 **[00153]** 2- Quantitatively transfer ethanol, triethyl citrate, transcitol, and propylene glycol. Using a suitable mixer, mix until complete dissolution.

[00154] 3- Add lactic acid and mix well.

- [00155]** 4- In separate container weigh water and add sodium lauryl sulfate. Mix until complete dissolution.
- [00156]** 5- Slowly add item from step 4 to item from step 3. Mix until complete dissolution. Avoid excessive stirring to prevent foaming.
- 5 (c) Preparation of Ibuprofen formulation (IB 456)
- [00157]** 1- Weigh Ibuprofen in a suitable container.
- [00158]** 2- Quantitatively transfer ethanol, triethyl citrate and propylene glycol. Using a suitable mixer, mix until complete dissolution.
- [00159]** 3- Add lactic acid and mix well.
- 10 **[00160]** 4- In separate container weigh water, add sodium lauryl sulfate and Amphosol. Mix until complete dissolution.
- [00161]** 5- Slowly add item from step 4 to item from step 3. Mix until complete dissolution. Avoid excessive stirring to prevent foaming.
- (d) Preparation of Ibuprofen formulation (IB 486)
- 15 **[00162]** 1- Weigh Ibuprofen in a suitable container.
- [00163]** 2- Quantitatively transfer ethanol, triethyl citrate and propylene glycol. Using a suitable mixer, mix until complete dissolution.
- [00164]** 3- Add lactic acid and mix well.
- [00165]** 4- In separate container weigh water, add Amphosol. Mix until
20 complete dissolution.
- [00166]** 5- Slowly add item from step 4 to item from step 3. Mix until complete dissolution. Avoid excessive stirring to prevent foaming.
- [00167]** Other formulations were prepared and representative examples are summarized in Table 1. These formulations can also be prepared using a
25 buffer instead of water. Additionally or alternatively, the pH value of the hydroalcoholic chassis and/or final composition can be adjusted using one or more pH adjusting agents.

Example 2: Exemplary Procedure for Skin Permeation Measurement

- [00168]** The permeation of ibuprofen through porcine skin from each of the present formulations was measured using Franz diffusion cells ("FDC"s). Porcine skin pieces are obtained from Lampire Biological Laboratories, Inc.,
5 Pipersville, PA. Porcine skins were collected immediately following animal sacrifice, and the hairs were trimmed with clippers. Larger pieces of excess fat were removed with a filet knife. The skin was then trimmed to a set thickness of some 2 mm, cut into individual pieces, wrapped in aluminum foil, frozen, shipped, and stored at -78 °C.
- 10 **[00169]** Prior to use, the skin pieces were allowed to thaw, in air, to room temperature. Before use, the skin was dermatomed to a thickness of 0.5 to 1 mm and cut into circular pieces of an appropriate size prior to mounting in the FDC. The FDCs had a 3-ml receptor well volume, that was filled with isotonic phosphate buffered saline ("PBS") doped with 0.01% sodium azide. The
15 flanges of the FDCs were coated with vacuum grease to ensure a complete seal and were clamped together with uniform pressure using a pinch clamp (SS #18 VWR 80073-350 from VWR Scientific, West Chester PA). After the FDCs were assembled, the porcine skin was optionally allowed to pre-hydrate for 45 min with isotonic PBS. Isotonic PBS was then removed and the
20 formulation was applied to the donor well or directly to the skin surface, depending on the amount of formulation applied. The receptor wells were maintained at 37°C (temperature on the surface of the skin is about 30 °C) in a stirring block with continual agitation via a stir bar.
- [00170]** The flux rates were calculated using the fact that the donor well
25 of each cell had an approximate area of 0.55 cm². Samples were drawn from the receptor wells at various times, as provided in the examples that follow. Franz diffusion cell measurements were typically made in six-fold replicates for each formulation. The concentrations of ibuprofen in the samples were measured using HPLC analysis using a C18 column and acetonitrile and
30 water as the mobile phase. Generally, in the examples that follow, permeation data were reported by plotting a curve showing the cumulative amount of

etoricoxib that permeates across the skin as a function of time. The flux rate can be computed as the time derivative of this curve.

[00171] All flux measurements reported herein are for the racemic (R/S) form of ibuprofen. Measurements have revealed no significant difference in
5 flux of the racemic form, compared to the (S) form (the form with substantially higher biological activity), when applied at the same total concentration in the same vehicle. Replacement of the racemic ibuprofen by Dex (S) ibuprofen in any of the formulations described herein is expected to provide a similar flux but about a 2x increase in efficacy [Mayrhofer F. *Efficacy and long-term safety of dexibuprofen [S(+)-ibuprofen]: a short-term efficacy study in patients with*
10 *osteoarthritis of the hip and a 1-year tolerability study in patients with rheumatic disorders.* Clin Rheumatol. 2001 Nov;20 Suppl 1:S22-9; Singer F, Mayrhofer F, Klein G, Hawel R, Kollenz CJ. *Evaluation of the efficacy and dose-response relationship of dexibuprofen (S(+)-ibuprofen) in patients with*
15 *osteoarthritis of the hip and comparison with racemic ibuprofen using the WOMAC osteoarthritis index.* Int J Clin Pharmacol Ther. 2000 Jan;38(1):15-24].

[00172] As shown in Table 2, compositions of the present application showed three to four times relative enhancement in flux of ibuprofen over a
20 comparative formulation (Ibugel™).

Example 3: Effect of Triethyl Citrate and Surfactants

[00173] Several ibuprofen (5% w/w) compositions were prepared without the addition of triethyl citrate and/or surfactants. All compositions prepared without both triethyl citrate and a surfactant showed immediate instability (e.g.
25 precipitation). All compositions prepared without either triethyl citrate or a surfactant showed instability (e.g. precipitation) after 24 hours.

Example 4: Effect of Addition of Thickening Agents

[00174] Formulations were prepared using the general procedure described in Example 1 that included 1% hydroxypropyl cellulose (HY121).
30 For example, formulation 449b (Example 1b) comprised 1% HY121 (see

Figure 1 with reference to Table 3 for identification of composition components). As can be seen from the bar graph in Figure 1, the addition of thickener did not cause a significant effect on the flux of ibuprofen.

Example 5: Effect of Combinations of Alcohols

5 [00175] Formulations were prepared using the general procedure described in Example 1 that included various combinations of alcohols. As can be seen in Figure 2 (with reference to Table 4 for identification of composition components) the alcohol combination of 14% transcitol, 10% propylene glycol and 20% ethanol in composition no. Ib449 provided optimum
10 results.

Example 6: Effect of Terpene Addition

[00176] Formulations were prepared using the general procedure described in Example 1 that included various terpenes. As can be seen in Figure 3 (with reference to Table 5 for identification of composition
15 components) terpene combinations had an enhancing effect on flux in certain compositions (see composition no. Ib402).

Example 7: Effect of Additional Solvents

[00177] Formulations were prepared using the general procedure described in Example 1 that included DMSO and/or dimethylacetamide (DMA)
20 as additional solvents. As can be seen in Figure 4 (with reference to Table 6 for identification of composition components), Figure 5 (with reference to Table 7 for identification of composition components) and Figure 6 (with reference to Table 8 for identification of composition components) in certain compositions DMSO alone or in combination with DMA had an optimum effect
25 (see composition nos. Ib332, Ib333, Ib340, Ib460, Ib461, IB469 and Ib470).

Example 8: Thickened Formulation

[00178] Formulation (IB949) was prepared based on Formulation No. IB486 (Table 1), using the following procedure. The formulation is presented
in Table 9.

30 [00179] Ibuprofen was first dissolved in the organic solvents (ethanol combined with Transcutol), followed by the addition of triethyl citrate,

propylene glycol, propyl and methyl parabens, sodium lauryl sulfate, D,L-lactic acid and approximately half of the water. After mixing and dissolving the components, the remainder of the water was added, followed by gradual introduction of the gelling agent. The composition was mixed overnight using
5 a mixer, or until no lumps and undispersed material was evident, if sooner. The process took ~20 hours to be completed. Any air bubbles that formed during the mixing process were found to disappear within ~ 30 min when the formulation was left to stand at room temperature ("RT").

Example 9: Effect of Modifying Thickened Formulations

10 **[00180]** Formulations were prepared based on Formulation No. IB949 (Table 9), using the general procedure described in Example 8.

[00181] The slate of compositions (Table 10) sampled variations in the amounts of sodium lauryl sulfate, triethyl citrate and lactic acid. Specifically, the levels of sodium lauryl sulfate were varied between 1 and 3%. The
15 amount of lactic acid was varied between 1 and 2%, and the level of triethyl citrate was adjusted between 0.5 and 1.0%. The concentration of water was held constant while the concentration of ethanol was adjusted commensurate with the changes in MPE™ concentrations.

[00182] Permeation profiles are shown in Figure 7. The Enhancement
20 Ratio (ER) for the individual formulations is provided at Table 11.

[00183] Formulation viscosities were measured at RT using a Brookfield viscometer (spindle #31). The measurements were made within 24 hrs of formulation preparation. Data showing formulation viscosities (centipoise) measured at differing rotation speeds (rotations per minute "rpm") are shown
25 at Table 12.

Results:

[00184] Based on the cumulative ibuprofen flux measured in the receptor well fluid at the end of the 24 h study, the following conclusions were reached:

30 **Sodium lauryl sulfate:** the optimal concentration of sodium lauryl sulfate is 2%; changing the sodium laurel sulfate concentration from 2% led to a reduction in ibuprofen delivery across the porcine skin (F2 vs F3 and F4);

Lactic acid: the optimal concentration of lactic acid appears to be 1.5% (F5, F6, and F7);

Triethyl citrate: Based on the present study the optimal concentration of triethyl citrate appears to be 2% since the reduction of triethyl citrate levels to 5 0.5 and 1.0 % led to diminished ibuprofen permeation (F2 vs F8, and F9).

[00185] The viscosity data indicated that all formulations have similar viscosities. However, formulation F7 (with 3% lactic acid) shows somewhat higher viscosity values, as shown in Table 12.

Example 10: Effect of pH and Lactic Acid

10 **[00186]** These studies were conducted to evaluate the role of pH on ibuprofen permeation and the effect of lactic acid concentration on citrate buffer levels. As can be seen in Figure 8 (with reference to Table 13 for identification of composition components) the permeation of ibuprofen was not significantly affected by pH. Similarly, in Figure 9 (with reference to Table 14 15 for identification of composition components) the permeation of ibuprofen was not significantly affected by the level of lactic acid on citrate buffer.

Example 11: Effect of Buffers

[00187] Formulations were prepared using the general procedure described in Example 1 or 8. The effect of including a buffer in the formulation 20 was measured in this study. The viscosity and pH of ingredient-modified formulations was also evaluated. As can be seen in Figures 10, 11 and 12 (with reference to Tables 15, 16 and 17, respectively, for identification of composition components) replacement of water by buffer, with or without final pH adjustment, did not significantly affect permeation behavior.

25 **[00188]** Tables 18 and 19 show the effect of removing ingredients on viscosity, while the effect of ingredients on pH are shown in Table 20. The removal of ingredients caused, to a certain degree, a shift in pH and change in viscosity of the final formulations.

Example 12: Effect of Varying Ingredient Concentration in Thickened Formulations

30

[00189] Formulations were prepared using the general procedure described in Example 8 and were based on IB949 with 2% HY 121 as thickener. In particular, the percentage of sodium lauryl sulphate was varied from 1-3%, the percentage of lactic acid was varied from 0.5-1.5% and the
5 percentage of triethyl citrate was varied from 0.5-1%. In further studies, triethyl citrate was substituted with other esters. pH and viscosities of the formulations were measured and are provided at Table 22.

[00190] As can be seen in Figure 13 (with reference to Table 21 for identification of composition components) an increase or decrease of sodium
10 lauryl sulphate reduced permeation of ibuprofen. Similarly, a change in lactic acid or triethyl citrate caused a drop in permeation. Substituting triethyl citrate with other esters, such as diisopropyl adipate, diethyl sebacate, ethyl oleate, isopropyl myristate and isopropyl palmitate, did not improve results.

Example 13: Optimized Formulation

15 [00191] An optimized formulation was prepared based on Formulation No. IB486 (Table 1), using the general procedure described in Example 1. The formulation is prepared in a PBS buffered system with a final pH adjusted to ~6.5. The formulation is shown at Table 23.

Example 14: General Method for Skin Retention Studies

20 [00192] At the end of the permeation study, skin samples can be removed from the Franz cells for skin retention studies. Any excess of formulation is carefully wiped away, first with cotton swabs and then with lint-free paper. The skin samples are quickly washed with cold water and ethanol, and the skin samples are then dried for 1 h at room temperature.
25 After being cut into small pieces with a pair of stainless steel scissors, the samples are transferred into 5 mL scintillation vials, and 2 mL of absolute ethanol is added. The samples are allowed to incubate for 24 h at room temperature. The liquid phase is then filtered through 9 mm diameter disposable syringe filters (0.45 μm , Acrodisc[®]). The filtrate, after appropriate
30 dilution, is assayed by HPLC.

[00193] While the present application has been described with reference to what are presently considered to be the preferred examples, it is to be understood that the application is not limited to the disclosed examples. To the contrary, the application is intended to cover various modifications and
5 equivalent arrangements included within the spirit and scope of the appended claims.

[00194] All publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and
10 individually indicated to be incorporated by reference in its entirety. Where a term in the present application is found to be defined differently in a document incorporated herein by reference, the definition provided herein is to serve as the definition for the term.

Table 1

Formulation name IB	257	229	340	402	332	333	391	426	413	427	449	449a	449b	456	460	461	469	470	486	493	594
Ingredients	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%
Softigen							3														
Triethyl Citrate	3	4.5	3	3	4.5	3		4.5	3	4.5	3	3	3	3	3	3	3	2	3	3	3
Amphosol		7.5	7.5		7.5	7.5		7.5		7.5				4	5	7.5	7.5	7.5	5	7.5	5
NA Lauryl Sulphate	2	2	2	2			2		2		2	2	2	1							
DMSO			10		10	10									5	10	10	10			
Ethanol	44	34	29	44	34	34	15	34	44	34	20	20	20	30	34	29	34	34	30	30	30
Water	44.5	47.5	39	40	37.5	39	33	44	38	41	44.5	43.5	43.5	41.5	41.5	39	40	39	31.5	19	21.5
Lactic Acid	1.5	1.5	1.5	1	1.5	1.5	1				1.5	1.5	1.5	1.5	1.5	1.5	1	1.5	1.5	1.5	1.5
Ibuprofen	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
Poloxamer 188							5														
Dimethyl-acetamide			5																		
Limonene							5														
α-Terpineol				5				5	5	5											
GL																					
Transcutol							10				14	14	14						20	14	14
GR									3												
IPM							3														
Tween 80							10														
PG							10				10	10	10	14	5				4	10	10
Isopropano															5						
HY 117											1										
HY 121												1									
Urea																					
D-Panthenol																					5
																					5

GL - Glycerin monolaurate
 GR - Glycerin monoricinoleate
 IPM - Isopropyl myristate
 PG - Propylene glycol
 HY 117 - Hydroxy propyl cellulose
 HY 121 - Hydroxy propyl cellulose NF

Table 2

5

Formulation name	Relative enhancement in flux
229	3.4
257	3.8
332	3.3
333	2.5
391	3.5-3.8
402	3.8
413	2.8
426	3.8
427	3.44
449	3.0-4.0
449a	2.0
449b	2.0-3.1
456	3.7-3.9
460	3.7-3.9
461	3.7
469	3.5-3.7
470	3.4
486	3.3-3.7
592	2.9-3.2
593	3.4-3.8
594	3.2-3.4

Table 3

Formulation name	lbugel	lb449	lb449a	lb449b	lb445	lb445a	lb445b	lb4520	lb520a	lb520b
Dosing (µl)	3	3	3	3	3	3	3	3	3	3
Ingredients	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%
Ibuprofen	5	5	5	5	5	5	5	5	5	5
Transcutol		14	14	14						
Isopropanol										
PG		10	10	10				14	14	14
Triethyl Citrate		2	2	2	1	1	1	3	3	3
Amphosol										
Na Lauryl Sulphate		2	2	2	2	2	2	2	2	2
Ethanol		20	20	20	44	44	44	30	30	30
Urea										
Water		44.5	44.5	44.5	46.5	46.5	46.5			
Lactic Acid		1.5	1.5	1.5	1.5	1.5	1.5			
Tween 20								1	1	1
Saline phosphate								45	45	45
Thickener Wt% added			HY117 1	HY121 1		HY117 1	HY121 1		HY117 1	HY121 1

Table 4

Formulation name	lbugel	lb449	lb450	lb451	lb452	lb453	lb455	lb456	lb433	lb438
Dosing (µl)	3	3	3	3	3	3	3	3	3	3
Ingredients	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%
Ibuprofen	5	5	5	5	5	5	5	5	5	5
Transcutol		14		14		10	15			
Isopropanol			14	10	14	14				
PG		10			10			14		
Tween 80										2
Triethyl Citrate		3	3	3	3	3	3	3	3	
Amphosol							4	4		
Na Lauryl Sulphate		2	2	2	2	2	1	1		
Ethanol		20	30	20	20	20	30	30	44	44
Cetrimonium Bromide									2	
Water		44.5	44.5	44.5	44.5	44.5	40.5	41.5	45	44
Lactic Acid		1.5	1.5	1.5	1.5	1.5	1.5	1.5	1	
Terpineol										5

Table 5

Formulation name	Ibugel	Ib257	Ib399	Ib401	Ib402	Ib403	Ib405	Ib407	Ib409	Ib410	Ib411	Ib413
Dosing (μ l)	3	3	3	3	3	3	3	3	3	3	3	3
Ingredients	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%
Ibuprofen	5	5	5	5	5	5	5	5	5	5	5	5
Triethyl Citrate		3	3	3	3	3	3	3	3	3	3	3
Amphosol												
Na Lauryl Sulphate		2	2	2	2	2	2	2	2	2	2	2
DMSO												
Ethanol		44	44	44	44	44	44	44	44	44	44	44
Water		44.5	37	37	40	37	37	38	38	41	38	38
Lactic Acid		1.5	1	1	1	1	1					
Limonene			5	5				5	5			
Terpineol					5		5			5	5	5
GL			3					3			3	
GR				3			3		3			3

Table 6

Formulation name	lbugel	lb331	lb332	lb333	lb334	lb335	lb336	lb337	lb338	lb340
Specs								layers	gel	gel
Dosing (μ l)	3	3	3	3	3	3	3	3	3	3
Ingredients	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%
Ibuprofen	5	5	5	5	5	5	5	5	5	5
Na Docusate										
Triethyl Citrate		4.5	4.5	3	4.5	4.5	3	4.5	4.5	3
PG										
Lactic Acid		1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
Amphosol			7.5	7.5		7.5	7.5		7.5	7.5
Dimethyl- acetamide					5	5	5	5	5	5
SNLS										
Ethanol		34	34	34	34	34	34	34	24	29
Water		45	37.5	39	50	42.5	44	45	47.5	39
DMSO		10	10	10				5	5	10

Table 7

Formulation name	Ibugel	Ib458	Ib459	Ib460	Ib461	Ib462	Ib463	Ib464	Ib465	Ib466	Ib467
Dosing (μ l)	3	3	3	3	3	3	3	3	3	3	3
Ingredients	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%
Ibuprofen	5	5	5	5	5	5	5	5	5	5	5
Triethyl Citrate		3	3	3	3	3	3	3	3	3	
Amphosol		7.5	7.5	5	7.5	7.5	7.5	7.5	7.5	5	7.5
Na Lauryl Sulphate											
DMSO		10	10	5	10	5	5	5	10	10	10
Ethanol		29	34	34	29	34	34	34	34	34	34
Isopropanol				5			5				
PG					5	5					
Transcutol								5	5		
Water		44	40.5	41.5	39	39	39	39	34	41.5	42
Lactic Acid		1.5		1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5

Table 8

Formulation name	Ibugel	Ib468	Ib469	Ib470	Ib471	Ib472	Ib473	Ib474	Ib475	Ib476
Dosing (μ l)	3	3	3	3	3	3	3	3	3	3
Ingredients	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%
Ibuprofen	5	5	5	5	5	5	5	5	5	5
Triethyl Citrate		3	3	2	3	3	3	3	3	3
Amphosol		7.5	7.5	7.5	7.5	7.5	7.5	7.5	7.5	5
Na Lauryl Sulphate										
DMSO			10	10						
Ethanol		34	34	34	34	34	35	29	29	29
Isopropanol					10		5	10	5	5
PG						10	5	5	10	5
Transcutol										
Water		49	39.5	40	39	39	38	39	39	46.5
Lactic Acid		1.5	1	1.5	1.5	1.5	1.5	1.5	1.5	1.5

Table 9

Ingredients:	IB949 (Percentages in (w/w))
Ibuprofen	5.0
Ethanol	30
Propylene glycol	10.0
Triethyl citrate	2.0
Diethylene glycol monoethyl ether [or (2-(2-ethoxyethoxy)ethanol); Transcutol]	14.0
Sodium lauryl sulfate	2.0
D,L-Lactic acid	1.5
Propyl paraben	0.1
Methyl paraben	0.1
Hydroxypropyl cellulose, HY 121	2.0
Water	33.3

Table 10

Ingredients	Formulations								
	F1 (Ibugel™)	F2 (IB949)	F3	F4	F5	F6	F7	F8	F9
Transcutol		14	14	14	14	14	14	14	14
Propylene glycol		10	10	10	10	10	10	10	10
Triethyl citrate		2	2	2	2	2	2	1	0.5
Sodium Lauryl sulfate		2	3	1	2	2	2	2	2
Ethanol		30	30	30	30	30	30	30	30
Water		33.3	32.3	34.3	34.3	33.8	32.8	34.3	34.8
D,L-Lactic acid		1.5	1.5	1.5	0.5	1	2	1.5	1.5
Propyl paraben		0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Methyl paraben		0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Ibuprofen		5	5	5	5	5	5	5	5
Hydroxypropyl cellulose, HY 121		2	2	2	2	2	2	2	2

Table 11

Formulation	Accumulated dose in ($\mu\text{g}/\text{cm}^2$)								
	F1 Ibugel	F2	F3	F4	F5	F6	F7	F8	F9
4hrs	0.3	2.6	0.7	1.1	1.4	1.1	1.3	0.6	1.4
SE	0.1	0.8	0.1	0.3	0.7	0.4	0.8	0.3	0.3
21hrs	11.8	36.8	24.7	28.7	25.8	33.2	29.3	23.8	29.8
SE	2	6.9	4.6	4.9	4.9	5.4	5.7	2.6	2.6
24hrs	14.4	39.4	27.2	31.2	28.3	35.8	32.7	26.2	32.6
SE	1.9	7.3	4.7	5.2	5.1	5.6	5.2	2.9	2.8
24hrs ER	1	2.7	1.9	2.2	2	2.5	2.3	1.8	2.3
SE	0.3	0.9	0.6	0.7	0.6	0.7	0.7	0.4	0.5

SE = standard error; ER = Enhancement Ratio

Table 12

rpm	F2	F3	F4	F5	F6	F7	F8	F9
0.5	19,196	25,375	23,695	25,675	22,015	34,773	26,094	27,054
0.6	18,396	24,345	22,295	23,445	21,245	26,664	24,845	25,295
0.7	17,782	23,438	21,595	22,881	20,053	25,923	23,352	23,995
0.8	17,284	22,570	20,808	22,420	19,383	24,820	22,308	22,983
0.9	16,463	21,829	20,196	21,662	18,929	21,529	21,529	21,995

Table 13

Formulation name	lbugel	lb949	lbct1pH	lbct1	lbct9pH	lbct9
Ingredients	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%
Ibuprofen	5	5	5	5	5	5
Transcutol		14	14	14	14	14
PG		10	10	10	10	10
Triethyl Citrate		2	2	2	2	2
Na Lauryl Sulphate		2	2	2	2	2
Ethanol		30	30	30	30	30
Water		33.3				
50mM citrate pH4.2			33.3	33.3		
50mM citrate pH4.8					33.3	33.3
PP		0.1	0.1	0.1	0.1	0.1
MP		0.1	0.1	0.1	0.1	0.1
Lactic Acid		1.5	1.5	1.5	1.5	1.5
HY 121		2	2	2	2	2
pH		4.27	4.18	4.29	4.29	4.9

Table 14

Formulation name	lbugel	lbCt1	lbCt1pH	lbCt4	lbCt4pH	lbCt17	lbCt17pH	lbCt20	lbCt20pH
Ingredients	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%
Ibuprofen	5	5	5	5	5	5	5	5	5
Transcutol		14	14	14	14	14	14	14	14
PG		10	10	10	10	10	10	10	10
Triethyl Citrate		2	2	2	2	2	2	2	2
Na Lauryl Sulphate		2	2	2	2	2	2	2	2
Ethanol		30	30	30	30	30	30	30	30
50mM citrate pH4.2		33.3	33.3	34.3	34.3				
100mM citrate pH4.2						33.3	33.3	34.3	34.3
PP		0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
MP		0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Lactic Acid		1.5	1.5	0.5	0.5	1.5	1.5	0.5	0.5
HY 121		2	2	2	2	2	2	2	2

Table 15

Formulation name	lbugel	lb949	lb950	lb951	lb952	lb953	lb954	lb955	lb956
Ingredients	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%
Ibuprofen	5	5	5	5	5	5	5	5	5
Transcutol		14	14	14	14	14	14	14	14
PG		10	10	10	10	10	10	10	10
Triethyl Citrate		2	2	2	2	2	2	1	0.5
Na Lauryl Sulphate		2	3	1	2	2	2	2	2
Ethanol		30	30	30	30	30	30	30	30
Water		33.3	32.3	34.3	34.3	33.8	32.8	34.3	34.8
PP		0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
MP		0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Lactic Acid		1.5	1.5	1.5	0.5	1	2	1.5	1.5
HY 121		2	2	2	2	2	2	2	2
pH		4.35	4.02	3.88	4.24	4.03	3.89	4.6	4.7

Table 16

Formulation name	Ibugel		Ib949		IbCt1pH		IbCt2pH		IbCt3pH		IbCt4pH		IbCt5pH		IbCt6pH		IbCt7pH		IbCt8pH	
	wt/	wt%	wt/	wt%	wt/	wt%	wt/	wt%	wt/	wt%	wt/	wt%	wt/	wt%	wt/	wt%	wt/	wt%	wt/	wt%
Ingredients	wt/	wt%	wt/	wt%	wt/	wt%	wt/	wt%	wt/	wt%	wt/	wt%	wt/	wt%	wt/	wt%	wt/	wt%	wt/	wt%
Ibuprofen	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
Transcutol	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14
PG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Triethyl Citrate	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	0.5
Na Lauryl Sulphate	2	2	2	2	1	1	3	3	1	1	2	2	2	2	2	2	2	2	2	2
Ethanol	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30
Water	33.3	33.3	33.3	33.3	33.3	33.3	33.3	33.3	33.3	33.3	33.3	33.3	33.3	33.3	33.3	33.3	33.3	33.3	33.3	33.3
50mM citrate pH4.2																				
PP	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
MP	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Lactic Acid	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	0.5	0.5	1	1	2	2	1.5	1.5	1.5	1.5
HY 121	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
pH	4.3	4.39	4.25	4.25	4.3	4.3	4.31	4.31	4.3	4.3	4.31	4.31	4.28	4.28	4.33	4.33	4.32	4.32	4.15	4.15

Table 17

Formulation name	lbugel	lb949	lbct1pH	lbct1	lbct9pH	lbct9
Ingredients	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%
Ibuprofen	5	5	5	5	5	5
Transcutol		14	14	14	14	14
PG		10	10	10	10	10
Triethyl Citrate		2	2	2	2	2
Na Lauryl Sulphate		2	2	2	2	2
Ethanol		30	30	30	30	30
Water		33.3				
50mM citrate pH4.2			33.3	33.3		
50mM citrate pH4.8					33.3	33.3
PP		0.1	0.1	0.1	0.1	0.1
MP		0.1	0.1	0.1	0.1	0.1
Lactic Acid		1.5	1.5	1.5	1.5	1.5
HY 121		2	2	2	2	2
pH		4.27	4.18	4.29	4.29	4.9

Table 18

Formulation	Ib949	Ib949-1	Ib949-2	Ib949-3	Ib949-4	Ib949-5	Ib949-6	Ib949-7	Ib949-8	Ib949-2*	Ib949-9
Ingredients											
Transcutol	14	14	14	14	14	14	14	14	14	14	14
Propylene glycol	10	10	10	10	10	10	10	10	10	10	10
Triethyl citrate	2	2	2	0	0	0	0	0	2	2	2
Na Lauryl sulfate	2	2	0	2	2	0	0	0	2	0	0
Ethanol	30	30	30	30	30	30	30	30	30	30	30
Water	qs 100	qs 100	qs 100	qs 100	qs 100	qs 100	qs 100	qs 100	qs 100	qs 100	qs 100
Lactic acid	1.5	0	0	1.5	0	0	0	0	1.5	0	0
Propyl paraben	0.1	0.1	0.1	0.1	0.1	0.1	0	0	0.1	0.1	0
Methyl paraben	0.1	0.1	0.1	0.1	0.1	0.1	0	0	0.1	0.1	0
Ibuprofen	5	5	5	5	5	5	5	0	1	5	0
HPC HY121	2	2	2	2	2	2	2	2	2	2	2
pH	4.45	3.95	3.65	3.38	4.17	3.4	3.48	4.99	3.33	3.41	4.18

*pH of Ib949-2 was measured 2 days later

Table 19

Viscosity with spindle 31RPM speed	lb949-1 (cP)	lb949-2 (cP)	lb949-3 (cP)	lb949-4 (cP)	lb949-5 (cP)	lb949-6 (cP)	lb949-7 (cP)	lb949-8 (cP)	lb949-9 (cP)	lb949-9 (cP)
0.5	19016	15837	18116	18656	11817	21235	13737	22135	13497	13497
0.6	18346	15047	16696	17446	10848	20096	13547	20496	12547	12547
0.7	17953	14440	16111	17182	10755	19025	13326	19453	12340	12340
0.8	17471	13947	15672	16759	10485	18071	12860	18709	11698	11698
0.9	16963	13297	15230	16430	10130	17330	12431	17863	11464	11464

Table 20

Ingredients	ib949	Transcutol	PG	Triethyl Citrate	Na Lauryl Sulfate	Ethanol	Lactic Acid	PP	MP	HY121
Transcutol	14	14								
PG	10		10							
Triethyl citrate	2			2						
Na Lauryl sulfa	2				2					
Ethanol	30					30				
Water		86	90	98	98	70	98.5	99.9	99.9	98
Lactic acid	1.5						1.5			
PP	0.1							0.1		
MP	0.1								0.1	
HY121	2									2
pH- water		7.72	7.73	7.86	7.75	7.89	7.75	7.67	7.65	7.58
pH- water and ingredients		4.32	6.97	3.72	7.97	7.31	2.4	6.13	5.72	6.43

Table 21

Formulation name	lbugel	lb949	lb950	lb951	lb952	lb953	lb954	lb955	lb956
Ingredients	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%	wt/ wt%
Ibuprofen	5	5	5	5	5	5	5	5	5
Transcutol		14	14	14	14	14	14	14	14
PG		10	10	10	10	10	10	10	10
Triethyl Citrate		2	2	2	2	2	2	1	0.5
Na Lauryl Sulphate		2	3	1	2	2	2	2	2
Ethanol		30	30	30	30	30	30	30	30
Water		33.3	32.3	34.3	34.3	33.8	32.8	34.3	34.8
PP		0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
MP		0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Lactic Acid		1.5	1.5	1.5	0.5	1	2	1.5	1.5
HY 121		2	2	2	2	2	2	2	2

Table 22

	RPM	Visc spindle #63	RPM	Visc spindle #64		RPM	Visc spindle #63	RPM	Visc spindle #64
lb949					lb953				
	10	1344	10	6239		10	1380	10	7318
	15	1160	15	5439		15	1200	15	6359
	20	1074	20	4979		20	1098	20	5789
	25	989	25	4583		25	1017	25	5351
	30	916	30	4279		30	944	30	4979
lb950					lb954				
	10	1356	10	7318		10	5291	10	24955
	15	1184	15	6279		15	4359	15	21555
	20	1080	20	5729		20	3755	20	19016
	25	993	25	5327		25	3345	25	16892
	30	924	30	4819		30	3027	30	15517
lb951					lb955				
	10	1248	10	6659		20	1380	20	7138
	15	1088	15	5759		25	1200	25	6199
	20	1008	20	5279		30	1098	30	5699
	25	931	25	4823		35	1022	35	5303
	30	860	30	4479		40	944	40	4979
lb952					lb956				
	10	1368	10	7318		20	1406	20	7258
	15	1192	15	6359		25	1224	25	6319
	20	1092	20	5789		30	1120	30	5759
	25	1013	25	5351		35	1032	35	5327
	30	944	30	4979		40	956	40	4959

Formulation	lb949	lb950	lb951	lb952	lb953	lb954	lb955	lb956
pH	4.05	4.02	3.88	4.24	4.03	3.89	4.6	4.7

Table 23

Ingredients	wt/wt %
Ibuprofen	5
PBS*	30.3
EtOH	30
PG	4
Amphosol	5
Transcutol	20
Lactic Acid	1.5
Triethyl Citrate	2
Methyl Paraben	0.1
Propyl Paraben	0.1
HPC HY121	2

*The gel formulation is prepared in a PBS buffered system with the final pH adjusted to ~6.5

Claims:

1. A composition comprising ibuprofen, a hydroalcoholic-based solvent, a C₁₋₄alcohol ester of citric acid and a surfactant, wherein the composition is formulated for topical administration.

5


2. The composition of claim 1, comprising about 0.1% (w/w) to about 10% (w/w), about 0.5% (w/w) to about 9.0% (w/w), about 1.0% (w/w) to about 8.0% (w/w), about 2.0% (w/w) to about 7.0% (w/w), about 3.0% (w/w) to about 6.5% (w/w), about 4.0% (w/w) to about 6.0% (w/w) or about 5% (w/w) of ibuprofen.

10

3. The composition of claim 1 or claim 2, wherein the ibuprofen is racemic (*R/S*)-ibuprofen or (*S*)-ibuprofen.

4. The composition of any one of claims 1 to 3, wherein the C₁₋₄alcohol ester of citric acid is a compound of the formula:

15



wherein at least one, two, three or four, of R^a, R^b, R^c and R^d are simultaneously or independently straight or branched chain C₁₋₄alkyl, the remainder of R^a, R^b, R^c and R^d being H.

20

5. The composition of claim 4, wherein R^a, R^b and R^c are the same and are selected from methyl, ethyl, propyl, butyl, isopropyl, isobutyl and t-butyl and R^d is selected from H and methyl.

25

6. The composition of any one of claims 1 to 3, wherein the C₁₋₄alcohol ester of citric acid is triethyl citrate.

7. The composition of any one of claims 1 to 6, comprising about 0.5% (w/w) to about 5% (w/w), about 1.5% (w/w) to about 4.5% (w/w), about 2.0% (w/w) to about 4.0% (w/w) or about 3% (w/w) of the C₁₋₄alcohol ester of citric acid.

5


8. The composition of any one of claims 1 to 7, wherein the surfactant is an anionic surfactant or a zwitterionic surfactant, or a mixture thereof.

9. The composition of claim 8, wherein the anionic surfactant comprises a sulfate anion.

10. The composition of claim 9, wherein the anionic surfactant is selected from sodium lauryl sulfate, ammonium lauryl sulfate and sodium dodecyl sulfate, and mixtures thereof.

15

11. The composition of claim 8, wherein the zwitterionic surfactant is an *N*-(cocoalkyl) amidopropyl betaine having the general formula:



20 wherein R is an alkyl chain comprising 9, 11, or 13 carbon atoms.

12. The composition of any one of claims 1 to 11, comprising about about 0.5% (w/w) to about 20% (w/w), about 0.75% (w/w) to about 15% (w/w), 1.0% (w/w) to about 10% (w/w), about 1.5% (w/w) to about 9% (w/w) or about 2.0% (w/w) to about 8.0% (w/w) of one or more surfactants.

25

13. The composition of any one of claims 1 to 7, comprising an anionic surfactant as the only surfactant.

14. The composition of claim 13, wherein the anionic surfactant is sodium lauryl sulfate.
15. The composition of claim 14, comprising about 0.5% (w/w) to about 5%
5 (w/w), about 1.0% (w/w) to about 4.0% (w/w), about 1.5% (w/w) to about 3.0% (w/w) or about 2% (w/w) of sodium lauryl sulfate.
16. The composition of any one of claims 1 to 7, comprising a zwitterionic surfactant.
- 10 17. The composition of claim 16, wherein the zwitterionic surfactant is an *N*-(cocoalkyl) amidopropyl betaine.
18. The composition of claim 17, comprising about 1.0% (w/w) to about
15 10% (w/w), about 2.0% (w/w) to about 9.0% (w/w), about 3.0% (w/w) to about 8.0% (w/w) or about 4.0% (w/w) to about 6.0% (w/w) of the *N*-(cocoalkyl) amidopropyl betaine.
19. The composition of any one of claims 1 to 7, comprising both an
20 anionic and a zwitterionic surfactant.
20. The composition of claim 19, wherein the anionic surfactant comprises a sulfate anion.
- 25 21. The composition of claim 19 or 20, wherein the zwitterionic surfactant is an *N*-(cocoalkyl) amidopropyl betaine.
22. The composition of any one of claims 19 to 21, comprising about 2.0% (w/w) to about 10% (w/w), about 3.0% (w/w) to about 9.0% (w/w) or about
30 4.0% (w/w) to about 8.0% (w/w) of combined total surfactant.

23. The composition of any one of claims 19 to 22, wherein the ratio of zwitterionic to anionic surfactant is about 10:1 to about 2:1 or about 4:1.

24. The composition of any one of claims 1 to 23, further comprising a
5 nonionic surfactant.

25. The composition of claim 24, wherein the nonionic surfactant is selected from alkyl poly(ethylene oxide), poloxamers, alkyl polyglcosides, fatty alcohols, polysorbates, glycerine esters, and alkyl-poly(ethylene oxide) ethers
10 and mixtures thereof.

26. The composition of claim 24, wherein the nonionic surfactant is present in the composition in an amount of about 0.1% (w/w) to about 20% (w/w), about 1.0% (w/w) to about 15% (w/w) or about 2.0% (w/w) to about 10.0%
15 (w/w).

27. The composition of any one of claims 24 to 26, wherein the composition comprises about 0.5% (w/w) to about 20% (w/w), about 0.75% (w/w) to about 15% (w/w), about 1.0% (w/w) to about 10% (w/w), about 2.0%
20 (w/w) to about 9.0% (w/w), about 3.0% (w/w) to about 8.0% (w/w) or about 4.0% (w/w) to about 6.0% (w/w) of combined total surfactant.

28. The composition of any one of claims 1 to 27, comprising about 10% (w/w) to about 60% (w/w), about 15% (w/w) to about 55% (w/w) or about 20%
25 (w/w) to about 50% (w/w) of water and about 10% (w/w) to about 60% (w/w), about 15% (w/w) to about 55% (w/w) or about 20% (w/w) to about 50% (w/w) of alcohol.

29. The composition of claim 28, wherein the alcohol is a lower alkyl
30 alcohol or a mixture of lower alkyl alcohols.

30. The composition of claim 28, wherein the alcohol is a monohydric alcohol.
- 5 31. The composition of claim 30, wherein the alcohol is ethanol, isopropanol, or 2-(2-ethoxyethoxy)ethanol (transcutol), or a mixture thereof.
32. The composition of claim 29, wherein the lower alcohol is a diol, or a mixture of diols.
- 10 33. The composition of claim 30 or 31, additionally comprising a diol.
34. The composition of claim 32 or 33, wherein the diol is selected from propylene glycol, butanediol, butynediol, pentanediol, hexanediol, octanediol,
15 neopentyl glycol, 2-methyl-1,3-propanediol, diethylene glycol, triethylene glycol, tetraethylene glycol, dipropylene glycol and dibutylene glycol, and mixtures thereof.
35. The composition of claim 34, wherein the diol is propylene glycol.
- 20 36. The composition of claim 35, comprising about 0% (w/w) to about 20% (w/w), about 1.0% (w/w) to about 15% (w/w) or about 4% (w/w) to about 15% (w/w) of propylene glycol.
- 25 37. The composition of any one of claims 1 to 36, comprising additional solvents.
38. The composition of claim 37, wherein the additional solvents are selected from D-panthenol, dimethylsulfoxide (DMSO) and dimethylacetamide
30 (DMA), and mixtures thereof.

39. The composition of claim 37 or 38, comprising about 0% (w/w) to about 20% (w/w), about 1.0% (w/w) to about 15% (w/w) or about 4% (w/w) to about 15% (w/w) of the additional solvents.

5 40. The composition of any one of claims 1 to 39, comprising a pH adjusting agent.

41. The composition of claim 40, wherein the pH adjusting agent is lactic acid.

10

42. The composition of claim 40 or 41, comprising about 0.1% (w/w) to about 5% (w/w), about 0.25% (w/w) to about 4% (w/w), about 0.5% (w/w) to about 3.0% (w/w), about 0.75% (w/w) to about 2.0% (w/w) or about 1.0% (w/w) of the pH adjusting agent.

15

43. The composition of any one of claims 1 to 42, comprising at least one thickening agent.

44. The composition of claim 43, wherein the thickening agent is a
20 cellulosic thickening agent.

45. The composition of claim 44, wherein the cellulosic thickening agents is selected from hydroxypropyl cellulose (HPC) of various grades, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hydroxyethyl methyl cellulose, ethyl
25 cellulose, methyl cellulose, carboxymethyl cellulose, dextran, guar gum, pectin, starch and cellulose, and mixtures thereof.

46. The composition of claim 45, wherein the cellulosic thickening agent is HPC.

30

47. The composition of any one of claims 43 to 46, comprising 0.0% (w/w) to about 5% (w/w), about 0.1% (w/w) to about 4% (w/w), about 0.5% (w/w) to

about 3.0% (w/w), about 0.75% (w/w) to about 2.0% (w/w) or about 1.0% (w/w) of the thickening agent.

48. The composition of any one of claims 1 to 47, comprising 0.0% (w/w) to
5 about 10% (w/w), about 1.0% (w/w) to about 9% (w/w), about 2.0% (w/w) to
about 8.0% (w/w), about 3.0% (w/w) to about 7.0% (w/w), about 4.0% (w/w) to
about 6.0% (w/w) or about 5% (w/w) of D-panthenol.

49. The composition of any one of claims 1 to 48, further comprising a
10 terpene.

50. The composition of claim 49, wherein the terpene is a monoterpene
selected from limonene and α -terpineol, and mixtures thereof.

15 51. The composition of claim 49 or 50, wherein the terpenes are present in
the composition in an amount of 0.0% (w/w) to about 10% (w/w), about 1.0%
(w/w) to about 9% (w/w), about 2.0% (w/w) to about 8.0% (w/w), about 3.0%
(w/w) to about 7.0% (w/w), about 4.0% (w/w) to about 6.0% (w/w) or about 5%
(w/w).

20

52. The composition of any one of claims 1 to 49, further comprising about
0.0% (w/w) to about 10% (w/w), about 1.0% (w/w) to about 9% (w/w), about
2.0% (w/w) to about 8.0% (w/w), about 3.0% (w/w) to about 7.0% (w/w), about
4.0% (w/w) to about 6.0% (w/w) or about 5% (w/w) of urea.

25

53. The composition of any one of claims 1 to 52, in the form of a spray, a
gel, a cream, an emulsion, a microemulsion, a lotion, an organogel, an
ointment, a solution, or a transdermal patch.

30 54. The composition of any one of claims 1 to 52, having an ibuprofen flux
that is at least 2.0, 3.0 or 4.0 times greater than the ibuprofen flux of a
comparative composition.

55. The composition of claim 54, wherein the comparative solution is a topical aqueous/alcoholic gel comprising ibuprofen (5% wt/wt), ethanol, carbomer, propylene glycol, diethylamine and purified water.

5

56. The composition of claim 1, comprising, consisting essentially of or consisting of ibuprofen, ethanol, water, triethyl citrate, lactic acid and sodium lauryl sulfate.

10 57. The composition of claim 56, comprising, consisting essentially of or consisting of:

about 1% (w/w) to about 10% (w/w) ibuprofen;
about 40% (w/w) to about 50% (w/w) ethanol;
about 40% (w/w) to about 50% (w/w) water;
15 about 2% (w/w) to about 5% (w/w) triethyl citrate;
about 0.5% (w/w) to about 2.5% (w/w) lactic acid; and
about 1% (w/w) to about 3% (w/w) sodium lauryl sulfate.

58. The composition of claim 56 or 57, wherein the ethanol is replaced with
20 a mixture of alcohols.

59. The composition of claim 58, wherein the mixture of alcohols comprises alcohols selected from ethanol, polyglycol and transcitol and mixtures thereof.

25

60. The composition of claim 59, comprising, consisting essentially of or consisting of:

about 1% (w/w) to about 10% (w/w) ibuprofen;
about 15% (w/w) to about 25% (w/w) ethanol;
30 about 10% (w/w) to about 20% (w/w) transcitol;
about 5% (w/w) to about 15% (w/w) propylene glycol;
about 25% (w/w) to about 45% (w/w) water;

about 1% (w/w) to about 5% (w/w) triethyl citrate;
about 0.5% (w/w) to about 2.5% (w/w) lactic acid; and
about 1% (w/w) to about 3% (w/w) sodium lauryl sulfate.

5 61. The composition of claim 1, comprising, consisting essentially of or
consisting of ibuprofen, ethanol, water, triethyl citrate, lactic acid, propylene
glycol, *N*-(cocoalkyl) amidopropyl betaine and sodium lauryl sulfate.

62. The composition of claim 61, comprising, consisting essentially of or
10 consisting of:

about 1% (w/w) to about 10% (w/w) ibuprofen;
about 25% (w/w) to about 35% (w/w) ethanol;
about 10% (w/w) to about 20% (w/w) propylene glycol;
about 35% (w/w) to about 45% (w/w) water;
15 about 2% (w/w) to about 5% (w/w) triethyl citrate;
about 0.5% (w/w) to about 2.5% (w/w) lactic acid;
about 1% (w/w) to about 3% (w/w) sodium lauryl sulfate; and
about 2% (w/w) to about 10% (w/w) *N*-(cocoalkyl) amidopropyl
betaine.

20

63. The composition of claim 1, comprising, consisting essentially of or
consisting of ibuprofen, ethanol, water, triethyl citrate, lactic acid, transcitol,
propylene glycol and *N*-(cocoalkyl) amidopropyl betaine.

25 64. The composition of claim 63, comprising, consisting essentially of or
consisting of:

about 1% (w/w) to about 10% (w/w) ibuprofen;
about 25% (w/w) to about 35% (w/w) ethanol;
about 15% (w/w) to about 25% (w/w) transcitol;
30 about 1% (w/w) to about 10% (w/w) propylene glycol;
about 25% (w/w) to about 35% (w/w) water;
about 2% (w/w) to about 5% (w/w) triethyl citrate;

about 0.5% (w/w) to about 2.5% (w/w) lactic acid; and
about 2% (w/w) to about 10% (w/w) *N*-(cocoalkyl) amidopropyl
betaine.

5 65. The composition of claim 1, comprising, consisting essentially of or
consisting of ibuprofen, ethanol, water, triethyl citrate, lactic acid, DMSO and
N-(cocoalkyl) amidopropyl betaine.

10 66. The composition of claim 65, comprising, consisting essentially of or
consisting of:

about 1% (w/w) to about 10% (w/w) ibuprofen;

about 30% (w/w) to about 40% (w/w) ethanol;

about 35% (w/w) to about 45% (w/w) water;

about 2% (w/w) to about 5% (w/w) triethyl citrate;

15 about 0.5% (w/w) to about 2.5% (w/w) lactic acid;

about 2% (w/w) to about 10% (w/w) *N*-(cocoalkyl) amidopropyl
betaine; and

about 5% (w/w) to about 15% (w/w) DMSO.

20 67. The composition of any one of claims 56 to 66, wherein the water
component is buffered.

68. The composition of claim 1, comprising, consisting essentially of or
consisting of ibuprofen, ethanol, phosphate buffered saline (PBS), triethyl
25 citrate, lactic acid, propylene glycol, amphosol and transcitol, wherein the pH
is adjusted to about 6.5.

69. The composition of claim 68, comprising, consisting essentially of or
consisting of:

30 about 1% (w/w) to about 10% (w/w) ibuprofen;

about 25% (w/w) to about 35% (w/w) ethanol;

5 about 15% (w/w) to about 25% (w/w) transcutol;
about 1% (w/w) to about 10% (w/w) propylene glycol;
about 25% (w/w) to about 35% (w/w) PBS;
about 1% (w/w) to about 5% (w/w) triethyl citrate;
about 0.5% (w/w) to about 2.5% (w/w) lactic acid; and
about 2% (w/w) to about 10% (w/w) amphosol,
wherein the pH is adjusted to about 6.5

10 70. The composition of any one of claims 56 to 69, additionally comprising
a cellulosic thickening agent, for example HPC, in an amount of about 0.5%
(w/w) to about 2.0% (w/w).

71. The composition of any one of claims 56 to 70, additionally comprising
at least one preservative.

15 72. A method for treating pain comprising applying an effective amount of
the topical ibuprofen composition of any one of claims 1 to 71 to a subject in
need thereof.

73. A use of the composition of any one of claims 1 to 71 for treating pain.

74. A composition of any one of claims 1 to 71 for use for treating pain.


20 75. The method of claim 72, the use of claim 73, or the composition of
claim 74, wherein the pain is acute pain due to minor strains, sprains and
contusions.

76. The method of claim 72, the use of claim 73, or the composition of
claim 74, wherein the pain is associated with inflammation.

25 77. The method of claim 72, the use of claim 73, or the composition of
claim 74, wherein the pain is associated with osteoarthritis.


1/13

Figure 1




2/13

Figure 2




3/13

Figure 3




4/13

Figure 4




5/13

Figure 5




6/13

Figure 6




7/13

Figure 7




8/13

Figure 8




9/13

Figure 9




10/13

Figure 10




11/13

Figure 11




12/13

Figure 12



13/13

Figure 13



INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2010/001899

A. CLASSIFICATION OF SUBJECT MATTER
 IPC: **A61K 47/14** (2006.01) , **A61K 31/192** (2006.01) , **A61P 29/00** (2006.01)
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC: **A61K 47/14** (2006.01) , **A61K 31/192** (2006.01) , **A61P 29/00** (2006.01)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used)
 STN CAPlus (keywords = ibuprofen, ethyl citrate, penetration enhancer, topical, homogeneity, hydroalcohol); Canadian Patent Database (IPC + keywords); TotalPatent (IPC + keywords)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CA 2,449,098 (Plachetka) 12 December 2002 (12-12-2002) *entire document*	1-71, 73-74
A	CA 2,680,825 (McCook et al.) 25 September 2008 (25-09-2008) *entire document*	1-71, 73-74
A	US 5,686,489 (Yu et al.) 11 November 1997 (11-11-1997) *entire document*	1-71, 73-74
A, P	US 2010/0221245 A1 (Kunin) 2 September 2010 (02-09-2010) *entire document*	1-71, 73-74

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

7 March 2011 (07-03-2011)

Date of mailing of the international search report

16 March 2011 (16-03-2011)

Name and mailing address of the ISA/CA
 Canadian Intellectual Property Office
 Place du Portage I, C114 - 1st Floor, Box PCT
 50 Victoria Street
 Gatineau, Quebec K1A 0C9
 Facsimile No.: 001-819-953-2476

Authorized officer
Tung Siu (819) 934-6735

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of the first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons :

1. Claim Nos. : 72, 75-77
because they relate to subject matter not required to be searched by this Authority, namely :

Claims 72 and 75-77 are directed to a method for treatment of the human or animal body by surgery or therapy which the International Search Authority is not required to search. However, this Authority has carried out a search based on the alleged effects or purposes/uses of the product defined in claims 72 and 75-77.
2. Claim Nos. :
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically :
3. Claim Nos. :
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows :

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claim Nos. :
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim Nos. :

- Remark on Protest**
- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
 - The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
 - No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/CA2010/001899

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
CA2449098A1	12 December 2002 (12-12-2002)	AT474559T	15 August 2010 (15-08-2010)
		AU2002305758C1	16 December 2002 (16-12-2002)
		AU2002305758B2	07 September 2006 (07-09-2006)
		AU2006235929A1	30 November 2006 (30-11-2006)
		AU2006235929B2	11 December 2008 (11-12-2008)
		AU2009200966A1	02 April 2009 (02-04-2009)
		AU2009200966B2	10 June 2010 (10-06-2010)
		CA2449098C	05 January 2010 (05-01-2010)
		DE60237087D1	02 September 2010 (02-09-2010)
		DK1411900T3	25 October 2010 (25-10-2010)
		EA006398B1	29 December 2005 (29-12-2005)
		EP1411900A2	28 April 2004 (28-04-2004)
		EP1411900A4	27 June 2007 (27-06-2007)
		EP1411900B1	21 July 2010 (21-07-2010)
		EP2163241A1	17 March 2010 (17-03-2010)
		EP2260837A1	15 December 2010 (15-12-2010)
		ES2348710T3	13 December 2010 (13-12-2010)
		IL159129D0	12 May 2004 (12-05-2004)
		JP2004536809T	09 December 2004 (09-12-2004)
		MXPA03011017A	29 April 2005 (29-04-2005)
		NO20035275D0	27 November 2003 (27-11-2003)
		PT1411900E	11 October 2010 (11-10-2010)
		US2003069255A1	10 April 2003 (10-04-2003)
		US6926907B2	09 August 2005 (09-08-2005)
		US2005249811A1	10 November 2005 (10-11-2005)
		US2010062064A1	11 March 2010 (11-03-2010)
		US2010172983A1	08 July 2010 (08-07-2010)
WO02098352A2	12 December 2002 (12-12-2002)		
WO02098352A3	26 June 2003 (26-06-2003)		
WO2010029335A1	18 March 2010 (18-03-2010)		
CA2680825A1	25 September 2008 (25-09-2008)	AU2008228764A1	25 September 2008 (25-09-2008)
		EP2136787A2	30 December 2009 (30-12-2009)
		MX2009010170A	26 November 2009 (26-11-2009)
		NO20093032A	22 October 2009 (22-10-2009)
		US2008233183A1	25 September 2008 (25-09-2008)
		WO2008116135A2	25 September 2008 (25-09-2008)
WO2008116135A3	24 December 2008 (24-12-2008)		
US5686489A	11 November 1997 (11-11-1997)	AT130187T	15 December 1995 (15-12-1995)
		AT177629T	15 April 1999 (15-04-1999)
		AT276733T	15 October 2004 (15-10-2004)
		AU618517B2	02 January 1992 (02-01-1992)
		AU654850B2	24 November 1994 (24-11-1994)
		AU660917B2	13 July 1995 (13-07-1995)
		AU664987B2	14 December 1995 (14-12-1995)
		AU701232B2	21 January 1999 (21-01-1999)
		AU701517B2	28 January 1999 (28-01-1999)
		AU701962B2	11 February 1999 (11-02-1999)
		AU1394392A	28 May 1992 (28-05-1992)
		AU1409492A	15 October 1992 (15-10-1992)
		AU1865499A	26 July 1999 (26-07-1999)
		AU1926592A	17 November 1992 (17-11-1992)
		AU2390599A	17 June 1999 (17-06-1999)
		AU3311095A	15 February 1996 (15-02-1996)
		AU3319295A	07 December 1995 (07-12-1995)
		AU5913990A	21 February 1991 (21-02-1991)
AU6035796A	30 December 1996 (30-12-1996)		
AU7998687A	23 June 1988 (23-06-1988)		

-/-- continued on extra sheet

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2010/001899

Continuation of Patent Family Annex:

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
US5686489A	11 November 1997	BR9205870A	27 September 1994 (27-09-1994)
		CA1324077C	09 November 1993 (09-11-1993)
		CA1339706C	10 March 1998 (10-03-1998)
		CA1340120C	10 November 1998 (10-11-1998)
		CA2019273A1	15 February 1991 (15-02-1991)
		CA2019273C	29 May 2001 (29-05-2001)
		CA2065664A1	11 October 1992 (11-10-1992)
		CA2223324A1	19 December 1996 (19-12-1996)
		CA2324972A1	15 July 1999 (15-07-1999)
		CA2337750A1	15 February 1991 (15-02-1991)
		CA2337750C	15 October 2002 (15-10-2002)
		DE508324T1	08 July 1993 (08-07-1993)
		DE3751361D1	27 July 1995 (27-07-1995)
		DE3751361T2	14 December 1995 (14-12-1995)
		DE3752045D1	07 May 1997 (07-05-1997)
		DE3752045T2	13 November 1997 (13-11-1997)
		DE69023574D1	21 December 1995 (21-12-1995)
		DE69023574T2	28 March 1996 (28-03-1996)
		DE69228622D1	22 April 1999 (22-04-1999)
		DE69228622T2	02 December 1999 (02-12-1999)
		DE69633443D1	28 October 2004 (28-10-2004)
		DE69633443T2	20 January 2005 (20-01-2005)
		DK0413528T3	11 March 1996 (11-03-1996)
		EP0273202A2	06 July 1988 (06-07-1988)
		EP0273202A3	06 June 1990 (06-06-1990)
		EP0273202B1	21 June 1995 (21-06-1995)
		EP0413528A1	20 February 1991 (20-02-1991)
		EP0413528B1	15 November 1995 (15-11-1995)
		EP0508324A2	14 October 1992 (14-10-1992)
		EP0508324A3	19 May 1993 (19-05-1993)
		EP0508324B1	17 March 1999 (17-03-1999)
		EP0599819A2	01 June 1994 (01-06-1994)
		EP0599819A3	27 July 1994 (27-07-1994)
		EP0599819B1	02 April 1997 (02-04-1997)
		EP0671162A2	13 September 1995 (13-09-1995)
		EP0671162A3	27 December 1995 (27-12-1995)
		EP0770399A2	02 May 1997 (02-05-1997)
		EP0831767A1	01 April 1998 (01-04-1998)
		EP0831767A4	17 May 2000 (17-05-2000)
		EP0831767B1	22 September 2004 (22-09-2004)
		EP1036178A1	20 September 2000 (20-09-2000)
		ES2039336T1	01 October 1993 (01-10-1993)
		ES2039336T3	01 August 1999 (01-08-1999)
		ES2074978T3	01 October 1995 (01-10-1995)
		ES2081936T3	16 March 1996 (16-03-1996)
		ES2103506T3	16 September 1997 (16-09-1997)
		ES2227590T3	01 April 2005 (01-04-2005)
		GR3018157T3	29 February 1996 (29-02-1996)
		GR93300044T1	21 June 1993 (21-06-1993)
		JP63166837A	11 July 1988 (11-07-1988)
		JP2533339B2	11 September 1996 (11-09-1996)
		JP5139947A	08 June 1993 (08-06-1993)
		JP2002500041T	08 January 2002 (08-01-2002)
		MX9203653A	01 September 1992 (01-09-1992)
		US5091171A	25 February 1992 (25-02-1992)
		US5091171B1	26 September 1995 (26-09-1995)
		US5091171B2	15 July 1997 (15-07-1997)
		US5385938A	31 January 1995 (31-01-1995)
		US5385938B1	15 July 1997 (15-07-1997)

-/-- continued on extra sheet

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2010/001899

Continuation of Patent Family Annex:

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
US5686489A	11 November 1997	US5422370B1	15 July 1997 (15-07-1997)
		US5470880A	28 November 1995 (28-11-1995)
		US5547988B1	15 July 1997 (15-07-1997)
		US5550158A	27 August 1996 (27-08-1996)
		US5554654A	10 September 1996 (10-09-1996)
		US5556882A	17 September 1996 (17-09-1996)
		US5561159A	01 October 1996 (01-10-1996)
		US5565487A	15 October 1996 (15-10-1996)
		US5578644A	26 November 1996 (26-11-1996)
		US5580902A	03 December 1996 (03-12-1996)
		US5583156A	10 December 1996 (10-12-1996)
		US5589505A	31 December 1996 (31-12-1996)
		US5591774A	07 January 1997 (07-01-1997)
		US5599843A	04 February 1997 (04-02-1997)
		US5612376A	18 March 1997 (18-03-1997)
		US5621006A	15 April 1997 (15-04-1997)
		US5637615A	10 June 1997 (10-06-1997)
		US5643963A	01 July 1997 (01-07-1997)
		US5648395A	15 July 1997 (15-07-1997)
		US5650440A	22 July 1997 (22-07-1997)
		US5652267A	29 July 1997 (29-07-1997)
		US5654340A	05 August 1997 (05-08-1997)
		US5656666A	12 August 1997 (12-08-1997)
		US5665776A	09 September 1997 (09-09-1997)
		US5668177A	16 September 1997 (16-09-1997)
		US5670543A	23 September 1997 (23-09-1997)
		US5674903A	07 October 1997 (07-10-1997)
		US5677340A	14 October 1997 (14-10-1997)
		US5681853A	28 October 1997 (28-10-1997)
		US5684044A	04 November 1997 (04-11-1997)
		US5691378A	25 November 1997 (25-11-1997)
		US5702688A	30 December 1997 (30-12-1997)
		US5716992A	10 February 1998 (10-02-1998)
		US5827882A	27 October 1998 (27-10-1998)
		US5834510A	10 November 1998 (10-11-1998)
		US5856357A	05 January 1999 (05-01-1999)
		US5883128A	16 March 1999 (16-03-1999)
		US5886042A	23 March 1999 (23-03-1999)
		US5889054A	30 March 1999 (30-03-1999)
		US5942250A	24 August 1999 (24-08-1999)
		US5962526A	05 October 1999 (05-10-1999)
		US6051609A	18 April 2000 (18-04-2000)
		US6060512A	09 May 2000 (09-05-2000)
		US6191167B1	20 February 2001 (20-02-2001)
		US6384079B1	07 May 2002 (07-05-2002)
		US6482609B1	19 November 2002 (19-11-2002)
		US2003083380A1	01 May 2003 (01-05-2003)
US6767924B2	27 July 2004 (27-07-2004)		
US2003054452A1	20 March 2003 (20-03-2003)		
US7052850B2	30 May 2006 (30-05-2006)		
US2003017130A1	23 January 2003 (23-01-2003)		
WO9218116A1	29 October 1992 (29-10-1992)		
WO9640047A1	19 December 1996 (19-12-1996)		
WO9935259A1	15 July 1999 (15-07-1999)		
US2010221245A1	02 September 2010) (02-09-2010)	None	